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Bone formation is a complex physiological process which is orchestrated by 
multiple microenvironmental cues such as soluble factors, cell-cell interactions and the 
extracellular matrix. Integrins are heterodimeric transmembrane receptors consisting of α 
and β subunits which mediate cell interactions with the extracellular matrix. Beta 1 
integrins encompass the majority of integrins and represent the main integrin binding 
partners of collagen I, the most abundant extracellular matrix component of bone. The 
central goals of this dissertation project were to elucidate the role of β1 integrins on bone 
development and healing in vivo, and to design biomimetic α2β1 integrin-specific 
polyethylene glycol hydrogels to enhance bone healing within segmental bone defects. 
Because global β1 knockout mice are embryonically lethal, in order to study the 
role of β1 integrins in vivo, we used the Cre-Lox system to generate mice with 
conditional beta 1 integrin deletions in osteolineage cells at three stages: (1) mesodermal 
cells [under Twist 2/Dermo 1], (2) osteoprogenitors [under the osterix promoter] and (3) 
mature osteoblasts and osteocytes [under the osteocalcin promoter]. We found that 
β1 integrin deletion in mesodermal cells severely impaired pre-natal skeletal 
mineralization, particularly in the calvarium, and also resulted in late-stage embryonic 
lethality. In contrast, β1 integrin deletion in pre-osteoblasts resulted in viable but runted 
mice with decreased cranial mineralization, tooth defects, impaired femur development 
and some perinatal mortality. Finally, mice with β1 integrin null osteoblasts and 
osteocytes displayed very mild bone phenotypes with no change in femur fracture healing 
capacity. Taken together, these results suggest that β1 integrins play an important role in 
xix 
 
the early bone formation process but are not essential for the function of mature 
osteoblasts and osteocytes. 
We also sought to engineer a biomimetic bone graft substitute by incorporating 
the following two bioactive components into a matrix metalloproteinase (MMP)-sensitive 
synthetic polyethylene glycol (PEG) hydrogel: (1) the collagen I-mimetic triple-helical 
synthetic ligand GFOGER, which specifically binds to the pro-osteogenic α2β1 integrin, 
and (2) recombinant human bone morphogenetic protein 2 (rhBMP-2). We synthesized 
PEG hydrogels incorporating GFOGER or the commonly used non-integrin selective 
adhesive peptide, RGD,  in equimolar densities and studied hMSC differentiation 
responses to each of these surfaces. We then examined the effects of treating murine 
radial segmental defects with either GFOGER functionalized PEG-MAL hydrogels or 
GFOGER gels which also incorporated a low dose of rhBMP-2. Our data indicated that 
GFOGER hydrogels enhanced bone healing compared to empty defects and that 
incorporating low dose rhBMP-2 in GFOGER gels further improved bone formation. We 
evaluated the roles of the GFOGER ligand and the MMP-sensitive crosslinker, 
GCRDVPMSMRGGDRCG (VPM), in this response by comparing bone formation in 
defects treated with non-degradable hydrogels, degradable hydrogels lacking the 
GFOGER ligand, and in defects treated with degradable GFOGER hydrogels. Minimal 
bone formation occurred in response to PEG hydrogels which were not functionalized 
with any adhesive ligand and there was no bone formation in non-degradable PEG 
hydrogels, indicating that adhesive function and degradability are essential to bone 
regeneration in response to GFOGER hydrogels. Our examination of rhBMP-2 dose 
response within GFOGER hydrogels suggested that low 0.02mg/ml (0.03 μg) dose was 
xx 
 
sufficient for robust healing, but that the medium 0.04 mg/ml (0.06 μg) dose increased 
bone volume and mineral density within the defect compared to the low dose. The high 
0.2 mg/ml (0.3 μg) BMP-2 dose induced less bone formation within the defect than the 
medium dose and altered the structure of the ulna so that it encircled the radius and fused 
with the radius. FMT analysis  and in vitro BMP release assays revealed that GFOGER 
hydrogels provided sustained release of rhBMP-2. Finally, we evaluated the bone 
regeneration capacity of low dose rhBMP-2 delivery from GFOGER functionalized PEG 
hydrogels in comparison with collagen sponges, the clinical standard for BMP-2 delivery. 
We observed superior bone healing in response to GFOGER hydrogel treatment. In 
conclusion, our bioengineered integrin-specific hydrogel may be a promising bone graft 





CHAPTER 1: SPECIFIC AIMS 
INTRODUCTION 
 Skeletal development and bone healing are complex processes involving multiple 
microenvironmental cues including extracellular matrix-integrin interactions. Integrins 
mediate important cell functions such as survival, adhesion, proliferation, migration and 
differentiation. The β1 integrin sub-family of integrins encompasses 12 out of 24 known 
integrins and primarily mediate cell adhesion to collagen I, the major ECM component of 
bone. β1 integrins, especially α2β1 integrins and α5β1 are highly expressed in 
mesenchymal stem cells and osteoprogenitors and are implicated in in vitro osteoblastic 
differentiation and mineralization
1-10
. Despite significant in vitro evidence that β1 
integrins play a crucial role in differentiation, in vivo perturbations of β1 integrins have 
yielded contradictory results as some conditional β1 integrin deletions have exhibited no 
skeletal phenotype
11, 12
, and dominant negative mutations have displayed only mild 
skeletal phenotypes
13
. Additionally, in the orthopedic biomaterials field, most ECM-
mimetic or bioadhesive strategies have not targeted the previously mentioned pro-
osteogenic integrins, but focused primarily on using the short RGD tripeptide sequence 
which is a promiscuous integrin binding partner.  
 Over 1 million bone grafting, bone excision and fracture repair procedures are 
performed each year in the United States, at cost of approximately $5 billion 
14-17
. While 
autografts are the gold standard treatment for large bone defects, they are limited by 
availability and donor site pain. Growth factor treatments such as BMP therapy provide a 
promising alternative but are expensive and present clinical safety concerns, primarily 
due to delivery of BMPs at supraphysiological doses. Therefore, there remains an unmet 
clinical need for safer, more effective bone graft substitute biomaterials. Understanding 
the role of integrins on bone formation and exploiting desirable ECM-integrin 
interactions may enable modulation of host cells for improved orthopaedic therapies.  
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 The two main objectives of this project are to (1) elucidate the role of β1 integrins 
on bone formation in vivo and (2) engineer a biofunctionalized α2β1 integrin-specific 
PEG hydrogel to promote bone healing in segmental defects. Our hypothesis is that β1 
integrins play an important early role in bone formation in vivo. We also hypothesize that 
degradable PEG hydrogels modified with the α2β1 integrin-specific ligand GFOGER will 
promote bone healing within a critical-sized defect in vivo. These objectives will be 
accomplished through the completion of the following aims: 
SPECIFIC AIM I 
Define the role of beta 1 integrins on bone formation by inducing targeted β1 
integrin deletions in osteolineage cells at three stages of differentiation: 1) 
mesodermal lineage cells, 2) osteoprogenitor cells, and 3) mature osteoblasts/ 
osteocytes. 
 β1 integrins are believed to play an important role in bone formation as β1 
integrins are highly expressed in osteoblasts, osteoprogenitors and bone marrow stromal 









 in these cells severely impairs in vitro osteogenic differentiation and 
mineralization. However, in vivo deletion or functional perturbation of β1 integrins 
results in only mild skeletal phenotypes. For example, transgenic mice expressing a 
dominant negative mutant form of the β1 integrin under the 1.8kb rat osteocalcin 
promoter display minor changes in skeletal development 
13, 18, 19
. These mild phenotypes 
include transient decreases in parietal thickness caused by increased osteoclast activity 
and altered canalicular structure in osteocytes
13
, decreased cancellous bone mass, 
decreased tibial curvature, and defective response to hindlimb unloading
18
, as well as 
transient decreases in tibial length, ash weight and dry weight, with no changes to femur 
mechanics
19
. β1 integrin deletion under the osteoblast-specific Col I 2.3kb promoter 
20
 
yielded no change in the skeletal structure of transgenic mice
11, 12
. Because β1 integrins 
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are essential for embryonic development, global β1 integrin knockout mice cannot be 
used for studies of in vivo β1 integrin function
21
. In order to evaluate the in vivo role of 
β1 integrins on bone formation, we will ablate β1 integrins in osteolineage cells at early, 
intermediate and late stages of differentiation by generating three different conditional 
knockout animals. Specifically, we will breed β1 integrin floxed mice with: 1) Twist 2 
Cre mice in order to delete β1 integrins in mesodermal lineage cells (Twist 2 Cre is 
expressed at E9.5 in brachial arches and somites and at E11.5 in mesenchymal 
condensations in mice), 2) Osterix Cre mice in order to ablate β1 integrins in 
osteoprogenitor cell (Osterix Cre mice express cre in committed osteoprogenitors in 
bones derived from both osteochondral and intramembranous ossification from E14.5 
onwards), and 3) Osteocalcin Cre mice to induce β1 integrin deletion in mature 
osteoblasts/ osteocytes. We hypothesize that β1 integrins play an important early role in 
skeletal development. 
SPECIFIC AIM II 
Evaluate the bone healing induced by GFOGER-modified PEG hydrogels 
incorporating low dose rhBMP-2 within segmental bone defects.  
 Although BMP therapies have shown promise as bone graft substitutes, due to 
limitations in release mechanisms of currently used biomaterial carriers, they are 
delivered at doses which far exceed physiological concentrations, resulting in high costs 
and potential complications
22-24
. Tissue engineering strategies for bone regeneration have 
largely focused on functionalizing materials with the promiscuous RGD peptide, which 
lacks of modulatory domains or other features found in native ECM ligands as well as 
specificity to pro-osteogenic integrins. Our group has previously engineered a collagen-
derived ligand, GFOGER, which mimics the triple helical structure of collagen to which 
cells adhere by specific binding of the 21 
25
 integrin, which is implicated in 
osteoblastic differentiation and mineralization. In this study, we engineered fully 
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synthetic, protease degradable PEG-maleimide hydrogels which incorporate the pro-
osteogenic GFOGER ligand and low-dose rhBMP-2. We hypothesized that by targeting 
the 21 integrin using the GFOGER adhesive ligand and by also providing sustained, 
‘on-demand’ release of low-dose rhBMP-2 we  could promote osteoblastic differentiation 
of host cells and promote bone regeneration in vivo. 
. 
SIGNIFICANCE 
 This work is significant and innovative because understanding β1 integrin effects 
on bone may have implications in regenerative medicine, and may further elucidate the 
mechanism of bone diseases which involve altered ECM interactions. Furthermore, the 
study of β1 integrins utilizes novel transgenic models to ablate β1 integrins in 
osteolineage cells at multiple different stages, whereas previous works have focused on 
conditional β1 integrin deletions in mature osteoblasts. The study of GFOGER/rhBMP-2 
hydrogels is innovative and significant because it will develop a completely synthetic, 
highly tunable biomaterial which focuses on engineering pro-osteogenic α2β1 integrin-
specificity in combination with controlled release of rhBMP-2 in order to induce robust 
bone regeneration. We expect that the development of GFOGER/low dose rhBMP-2 
hydrogels will represent a promising and clinically-relevant strategy for the treatment of 
large bone defects by promoting bone healing while also providing a potentially safe and 









 Integrins are a family of receptors which primarily mediate adhesion of cells to 
the extracellular matrix proteins such as collagen and fibronectin 
26
. Integrins are 
heterodimeric transmembrane proteins, each of which consists of  and  subunits. 
Currently, 8  and 18  integrin subunits are known, and these subunits associate non-
covalently to form 24 distinct  integrin combinations, each with unique binding 
characteristics (Figure. 2.1). X-ray crystallography analysis of integrin structure 
demonstrates a globular head connected to rod-like tails, and includes a flexible “knee” 
region which is involved in the activation state of the integrin. Integrins are capable of 
transducing signals in both directions across the cell membrane. For example, “outside-
in” signaling occurs when ECM ligation to integrins trigger intracellular signaling. 
Conversely, “inside-out” signaling takes place when intracellular signals modulate 
integrin activation state and thus change its affinity for its extracellular ECM ligand 
27
.  
Upon ECM binding to their extracellular domains, integrins cluster and their cytoplasmic 
domains associate with both cytoskeletal and intracellular signal transduction molecules. 
The association of integrins with the cellular signaling network initiates downstream 
signaling cascades such as the FAK, protein kinase C, Rac, Rho and MAPK pathways.  
_______________________________________ 
 
* Adapted from Shekaran, A., Garcia, A.J., Extracellular matrix-mimetic adhesive 
biomaterials for bone repair. J Biomed Mater Res A. 2011 96(1): 261-72
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The coordinated clustering of ECM ligands, integrins and cytoskeletal 
components forms macromolecular aggregates known as focal adhesions on the 
inside and outside of the cell membrane 
28
.  Because of the central roles of 
integrin-mediated adhesion to important cellular responses such as survival, 
growth, migration and differentiation 
27, 29, 30
, materials strategies which harness 
ECM-integrin interactions may play a key role in eliciting desired cellular 
responses in vivo. 
 
 
Figure 2.1. Integrin alpha and beta subunit combinations, binding specificity and 




INTEGRINS IMPLICATED IN BONE FORMATION 
 The 1 sub-family integrins are the mostly highly expressed integrins in 





osteoblasts may express the 3 and 5 subunits as well
32, 33
. α subunit expression data has 
been more inconsistent, with different combinations of 1, 2, 3, 4, 5 and v 
subunits having been detected by immunohistochemistry in human and rat bone
32-36
. The 
expression of the previously mentioned alpha subunits has also variously been 
determined by flow cytometry, immunoprecipitation, immunocytochemistry and 
Northern blot analysis on primary bone cultures
31-33, 37-40
.  Although reports of α subunit 
and integrin heterodimer expression in osteoblasts have sometimes been contradictory, 
multiple studies have identified the 11, 21, 31, 51, v3 integrins and their 
subunits in osteoblasts and bone cultures
31, 35, 39, 40
.  A few isolated studies have also 






  and v5
31
. Integrin expression 
studies on osteoprogenitor cells have shown similar profiles as osteoblasts, as Gronthos et 
al. reported the detection of 11, 21, 51, 61, v3 and v5 on STRO-1 
expressing human bone marrow stromal cells
6
 (Table 2.1, Figure. 2.1).  
 
Table 2.1. Composition of Bone Matrix. Composition of bone ECM. Itg – Integrins, Col 




Beta 1 Integrins  
Alpha 2 Beta 1 
 The 21 integrin is implicated in pro-osteogenic pathways as it is highly 
expressed by osteoblast-like cells and is a primary adhesion receptor used by osteoblast-
like cells to adhere to collagen
31
, the main organic component of bone. Several studies 
indicate that the interaction of 21 integrin with collagen I is a crucial signal for 
osteoblastic differentiation and matrix mineralization
3, 4, 41-44
. For example, 21-
mediated adhesion of MC3T3-E1 pre-osteoblasts to collagen I activates Runx2/Cbfa1, a 
transcription factor that activates osteoblastic differentiation and matrix mineralization
3, 
44
. 21 ligation to collagen I also induces the  phosphorylation of focal adhesion 
kinase (FAK) and activation of extracellular signal-related kinase (ERK), which has 
been implicated in the regulation  of osteoblast-specific gene expression and matrix 
mineralization
43-46
.  Silencing of the 2 integrin subunit also blocked human osteoblast-
like cell osteocalcin expression in response to micron-scale structure of titanium 
substrates
10
. Furthermore, the collagen–21 integrin interaction promotes an 
osteoblastic phenotype in rat multipotent bone marrow cells
41, 42
. Schneider et al also 
showed that perturbation of the 21 integrin resulted in a 95% reduction 
mineralization in an osteosarcoma cell line
47
. 
Alpha 5 Beta 1 
The 51 integrin plays an important role in osteogenic differentiation as it is 
expressed by osteoblasts and osteoprogenitors, and promotes cell survival and matrix 
mineralization. 51 is stably expressed by osteoblasts during varying stages of 
osteogenesis
8
 and is also expressed by bone marrow stromal cells
48
. In addition, 51 
also mediates cell attachment to fibronectin as well as fibronectin assembly
48
. In mature 
cells, 51 binding is necessary for cell survival and a decrease in 51-fibronectin 
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interaction leads to osteoblast apoptosis
49
 through a caspase-dependent mechanism
50
. 
51 may also be involved in mechanical sensing by osteoblasts in vitro
51
. Blockade of 
the 51 integrin inhibits bone-specific gene expression and mineralization in rat 
calvarial cultures
7, 8
 and a rat osteosarcoma cell line
47
. In human mesenchymal stromal 
cells (hMSC), priming the 5 subunit with an agonist or overexpression of the 5 
subunit increases osteogenic capacity
9
, while 51 blockade decreases the alkaline 
phosphatase activity of cells cultured on fibronectin
52
. 
Beta 3 Integrins  
Alpha v Beta 3 
 While engagement of the v3 integrin may support cell adhesion, it has a 
negative effect on the proliferation and differentiation of osteoprogenitors. Blocking of 
v3 has been shown to enhance human MSC proliferation on fibronectin and 
fibronectin fragments
52
. v3 may also inhibit osteoblast differentiation and bone 
healing in vivo. A murine osteoblastic cell line made to overexpress human αvβ3 
showed an increase in proliferation rate but a decrease in matrix mineralization
53
. 
Furthermore, early fracture healing was accelerated in the tibiae of β3-null mice and 
twenty-three genes related to osteogenesis were upregulated at least two-fold in the 
β3-null mice
54
. v3 also mediates osteoclast attachment to bone matrix and plays a 
central role in bone resorption
55, 56
. 
GLOBAL BETA 1 INTEGRIN KNOCKOUTS 
 Global β1 integrin knockout results in post-implantation embryonic lethality. 
Mouse embryos with homozygous 1 integrin deletion had collapsed blastocoels at E4.5 
and displayed severe degeneration at E5.5 due to inner cell mass (ICM) failure 
21
. A 
separate study also confirmed that mice with homozygous null 1 integrin mutations 
10 
 
underwent normal development to the blastocyst stage and implanted into the uterine 
wall, but failed shortly thereafter 
57
. In contrast, mice which were heterozygous for the 
null β1 integrin gene were indistinguishable from wild-type littermates despite having 
low (50%) expression levels of β1 integrins in the liver, kidney and brain, when 
compared to wild-type mice. In chimeric embryos established using 1 integrin-null, lacZ 
positive embryonic stem (ES) cells, the 1 integrin-deficient cells failed to colonize the 
liver and spleen, but were found to be present at varying levels ranging from 2-25% in all 
other tissues such as the brain, lung, heart and skeletal muscle 
57
. However, it should be 
noted that in this study, the presence or distribution of 1 integrin null cells was not 
analyzed in bone tissue. Taken together, these studies demonstrate that β1 integrins are 
not required for pre-implantation development, but β1 integrin gene mutation results in a 
recessive lethal defect in mouse embryonic development from E5.5 onwards.  
CRE-LOX SYSTEM FOR CONDITIONAL GENE DELETIONS 
 Cre-lox recombination is a sophisticated technology for genetic manipulation 
which allows for site-specific recombinase activity and may be used to generate global 
knockouts, conditional (tissue specific) knockouts or reporters
58
. The Cre-lox system 
requires two components: 1) Cre recombinase, an enzyme which catalyzes recombination 
between two loxP sites, and 2) loxP (locus of crossing [x-ing] over in P1) sites, specific 
34 base pair (bp) sequences consisting of a core 8bp sequence, where recombination 
takes place, flanked by two palindromic 13bp sequences (Figure. 2.2 A). When 
transgenic methods are used to insert loxP sites in the same orientation flanking a target 
gene, the outcome of Cre-induced loxP site-specific recombination is excision of DNA 
between the loxP sites, and therefore, deletion of the target gene 
59
 (Figure. 2.2 B).  
Transgenic animals with genomes in which target genes are flanked by loxP sites are 
termed as ‘floxed’ for the target gene 
60, 61
. If mice which are floxed also also express 
Cre-recombinase under a tissue-specific promoter, gene deletions in those animals will be 
11 
 
restricted to tissues which express that marker (Figure. 2.2 C). Conditional knockout 
animals may be useful in studying genes for which the global knockout results in prenatal 
lethality. 
 
Figure 2.2. Cre-Lox recombination technology. (A) loxP, or locus of crossing [x-ing] at 
P1 sites are specific 34 base pair sequences. (B) The enzyme cre-recombinase will excise 
any DNA sequence flanked by loxP sites with the same orientation, and this method can 
be used for gene deletions. (C) Cre expression under a tissue-specific promoter combined 
with the presence of a floxed gene in the same transgenic animal can be used to create 
conditional, tissue-specific gene deletions. 
12 
 
BONE STRUCTURE AND FUNCTION 
Bone cells 
Bone formation is regulated by osteoblasts, osteoclasts and osteocytes. 
Osteoblasts are mononucleate bone-forming cells which secrete osteoid, the non-
mineralized component of bone extracellular matrix and then mineralize the matrix
62
. 
Osteoblasts are derived from mesenchymal cells found in the periosteum or bone 
marrow. Osteoblasts express markers such as osterix, alkaline phosphatase, bone 
sialoprotein, osteocalcin, osteopontin and osteonetcin. After depositing and mineralizing 
osteoid, osteoblasts become embedded in the matrix and differentiate into osteocytes. 
Osteoblasts may also undergo apoptosis or differentiate into bone lining cells
62
.  
Osteoclasts are multinucleate cells which form when cells of the 
macrophage/monocyte lineage fuse together. Osteoclasts are polarized cells which resorb 
bone by secreting H+ ions through the ruffled border into the underlying matrix
62
.  
Osteocytes are derived from matrix embedded osteoblast. Osteocytes occupy 
lacunae and extend filapodia through canaliculi in the matrix. Osteocytes have a limited 
capacity to synthesize or resorb matrix
62
. 
Bone Extracellular Matrix  
 In bone, the ECM consists of mainly of an organic phase known as osteoid which 
constitutes approximately 20% of bone mass, and a mineral phase (Table 1). The organic 
fraction of bone consists of over 90% type I collagen
63
, other minor collagens such as 
types III and V, and 5% non-collagenous proteins. The non-collagenous proteins in bone 
include osteocalcin, osteonectin, osteopontin, adhesion proteins such as fibronectin and 
vitronectin and proteoglycans such as versican, decorin and hyaluronan
64
. The mineral 
phase of bone is composed of hydroxyapatite, a calcium phosphate compound. The bone 
13 
 
matrix also sequesters growth factors, acting as a reservoir for soluble inductive signals 
such as bone morphogetenic proteins (BMPs).  
 Bone ECM serves both structural and biological functions, as the mineralized 
matrix accounts for the tissue’s mechanical properties while it also provides chemical 
cues which regulate bone cells and acts as a reservoir for ions. Collagen fibrils provide 
tensile strength to bone and are composed of collagen helices which assemble parallel to 
each other in a regular quarter-staggered pattern, creating 68 nm gaps between adjacent 
collagen molecules. Hydroxyapatite crystals, which make up 70% of bone, fill these gaps 
and are responsible for the compressive strength of bone
62
. Bone ECM also regulates 
bone cells by providing ECM-integrin bonds which enable the formation of adhesive 
structures and activate signaling pathways which regulate cell spreading, survival and 
differentiation. 
CRE TRANSGENIC LINES USED FOR BONE-RELATED STUDIES 
Twist 2/ Dermo 1-Cre 
 Twist 2/ Dermo 1 is a basic helix-loop-helix (BHLH) protein 
65
 and a member of 
the Twist family of proteins which regulate the development of mesenchymal lineage 
cells and contribute to skeletal patterning. Like Twist 1, Twist 2 is believed to function as 
an inhibitor of myogenic or osteoblastic
66
 differentiation in mesenchymal stem cells 
(MSCs) and maintains MSCs in an undifferentiated state. Cre expression in Twist 2-Cre 
mice is observed at E9.5 in somites and brachial arches. At E11.5, cre expression occurs 
within mesenchymal condensations during endochondral ossification
67
. At E16.5, Twist 
2-Cre expression is detected in chondrocytes within the femoral growth plate as well as in 






 Osterix is a zinc finger protein that is expressed in committed osteoprogenitors in 
bones formed by both osteochondral and intramembranous ossification. In osterix-cre 
transgenic mice, cre expression is detected from E14.5 onwards in embryos
67
. In 10 day 
old mice, cre expression in Osterix-cre mice is observed in the perichondrium, 
periosteum, primary spongiosa, and in some hypertrophic chondrocytes as well. In 
osterix-cre mice, the cre recombinase protein is fused with GFP. 
Osteocalcin-Cre 
 Cre expression under the 3.5kb human Osteocalcin promoter has been observed in 
osteoblasts and osteocytes in mouse calvaria from E17 onwards
69
. Cre-mediated gene 
deletion under the Osteocalcin promoter is observed in the calvaria, femur and vertebrae 





 Skeletogenesis takes place in two stages. In the first stage, known as skeletal 
patterning, aggregates of mesenchymal cells called mesenchymal condensations form at 
the sites of future skeletal formation
62
. BMP signaling may occur earlier than this stage 
and is required for mesenchymal condensation. In mice, by day E10.5, most of the 
mesenchymal condensations have formed
71
. During the second phase, these 
mesenchymal condensations differentiate to form chondrocytes, osteoblasts and 
osteoclasts in a finely controlled process. Bones are formed either by endochondral 
ossification or intramembranous ossification. Long bones form through endochondral 
ossification, in which bone formation proceeds through the development of a cartilage 
template which is undergoes vascular invasion of bone cells and is remodeled and 
replaced with bone. In contrast, intramembranous ossification takes place in the 
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development of flat bones such as the calvarium and part of the clavicle by direct 
differentiation of cells in the mesenchymal condensations to bone
71
.  
 During endochondral ossification, cells in mesenchymal condensations 
differentiate into chondrocytes and begin to secrete type II Collagen. However, cells at 
the periphery of mesenchymal condensations form the perichondrium. At approximately 
E13.5 non-proliferating elongated pre-hypertrophic chondrocytes form in the middle of 
the mesenchymal condensations. When pre-hypertrophic chondrocytes begin to express 
type X Collagen, they become hypertrophic chondrocytes. At this time, cells in the 
perichondrium begin to express Runx2, the master regulator of osteoblastic 
differentiation
72
, forming the bone collar, which is the precursor to cortical bone. While 
hypertrophic chondrocytes undergo apoptosis, vascular invasion occurs through the bone 
collar, carrying osteoblast lineage cells into the center of the cartilage mold, which is now 
known as the primary spongiosa. These osteoblast lineage cells will subsequently form 
osteoblasts and deposit bone matrix in what will become trabecular bone. At the ends of 
each long bone, proliferating and hypertrophic chondrocytes align into columns to form 
the growth plate, which is responsible for lengthening of the bone
73
.  





, as well as Ihh
76
. The Sox9 and Runx2 
transcription factors are important regulators of hypertrophic chondrocytes. Sox9 is 
necessary for differentiation of mesenchymal cells into proliferating non-hypertrophic 
chondrocytes
77
. Runx2 inhibits chondrocyte proliferation and hypertrophy
78
. 
 Osteoblast differentiation is regulated by several proteins including Runx2, Twist 
1 and 2, as well as Osterix. Runx-2 is required for osteoblast differentiation, and Runx2 
knockouts never develop mineralized skeletons, and die of respiratory distress as 
newborns
79
. Osterix is expressed downstream of Runx2 and is also required for 
osteoblastic differentiation 
80
. Twist 1 and Twist 2 are also implicated in skeletogenesis. 
Twist 1 haploinsufficiency causes a form of craniosynostosis
81
. Twist 1 and 2 inhibit 
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osteoblastic differentiation of Runx2 expressing cells between E10.5 and E14.5 in the 
cranium and appendicular skeleton respectively
66
. Surprisingly, conditional deletion of 
BMP-2 under the Prx-1 promoter (an osteochondroprogenitor marker) does not inhibit 




BONE FRACTURE HEALING 
 Bone fracture healing occurs through a complex interplay of multiple cell types 
and cellular processes which recapitulates bone development and results in scar-free bone 
regeneration. Fracture healing may proceed through a combination of endochondral 
ossification and intramembranous ossification and occurs in multiple stages: (1) initial 
injury/inflammation, (2) endochondral formation/ periosteal response, (3) primary bone 
formation/ cartilage resorption, (4) secondary bone formation/ coupled remodeling. 
 The initial injury/inflammation stage takes place from approximately 0 to 7 days 
post fracture and is marked by hematoma formation, inflammation and mesenchymal 
stem cell recruitment.  Inflammation takes place during the first 24 hours, following 
which osteoprogenitor cells are recruited to the fracture site from the periosteum, bone 
marrow and surrounding tissues
83
. Proteases such as MMP-2 and MMP-14
84
 and multiple 
pro-inflammatory cytokines are upregulated during the first 7 days including MCSF, ILa, 
IL1b, IL6, IL11, RANKL, OPG, TNFα, and TNFβ. Morphogens which are highly 
expressed during this stage are BMP-2, TGFβ1 and GDF8. BMP-2 is expressed in a two-
phase profile, peaking once at day 1 and decreasing to a minimum at day 7 before 
increasing steadily again, peaking more strongly at 21 days and then decreasing again 
from 21-28 days post-fracture 
85, 86
. It is noteworthy that BMP-2 is the only BMP which 
is highly expressed during this early stage. Although BMP-2 is not required for bone 
development, it is required for fracture healing as conditional BMP-2 knockout mice with 
mid-diaphyseal femur fractures do not form a callus even after 20 days
82
. Mice lacking 
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BMP-2 do not have any periosteal activation at day 3 post-fracture, which suggests that 
BMP-2 is a crucial mediator of the early fracture healing response. 
 The endochondral formation/ periosteal response takes place from approximately 
7 to 14 days post fracture. During this stage, cartilage formation, vascular ingrowth and 
intramembranous bone formation take place. Cartilage-related ECMs such as Col2a1, 
Col10a1 and aggrecan are highly expressed. Morphogens such as TGFβ2, TGFβ3, as well 
as BMP-4, BMP-5 and BMP-6, GDF5, GDF10 and Indian hedgehog (Ihh) begin to be 
expressed. In addition, MMP-2, and MMP-14, ADAMTS-4 and ADAMTS-15  
expression continue to increase while MMP-9, MMP-13 begin to be highly expressed 
during the endochondral formation stage
84
. 
 During the primary bone formation stage, at approximately 14-28 days post 
fracture, chondrocytes undergo apoptosis, bone cells are recruited to the fracture callus, 
neovascularization occurs and osteoclasts are recruited to resorb calcified cartilage. 
Bone-related ECM proteins such as bone sialoprotein (BSP), osteopontin (OPN), and all 
BMPs are upregulated during this stage.  
 Finally, during the secondary bone formation stage, which occurs 3 weeks after 
fracture, bone marrow is established, the calcified cartilage is resorbed by osteoclasts, 
and bone remodeling takes place in order to replace woven bone with lamellar bone.  
 
BONE GRAFTS AND CLINICAL NEED 
 Although bone is unique in its capacity for scar-free regeneration in adults, large 
bone defects that occur due to traumatic injury, bone deformities or tumor resection are 
clinically challenging, and may result in non-unions or delayed unions 
87
.  These non-
healing bone defects will require treatment with bone grafts, which are also commonly 
used in spinal fusions, foot and ankle fusions as well as for reconstructions during 
revision surgeries for joint replacements. Over 1 million bone grafting, bone excision and 
18 
 
fracture repair surgeries are performed annually in the US, at cost of approximately $5 
billion 
14-17
. The worldwide bone graft substitute market was valued at $1.9 billion in 
2010 and is predicted to reach over $3.3 billion in 2017. Currently used bone graft 
products as well as their limitations are described below. 
Autografts and Allografts 
 Autografts are currently the gold standard of treatment for non-healing bone 
defects, followed closely in number of procedures performed by allografts 
22
.  Together, 
autograft and allograft tissue account for approximately 90% of bone graft treatments 
88
. 
Autografts are usually harvested from the patients iliac crest, distal femur or proximal 
tibia, but these treatments suffer from limited supply as well as chronic pain or 
inflammation at the donor site 
22
. Although donor and cadaveric allografts are more 
readily available than autografts, they carry the risk of immune rejection or transferring 
viral or bacterial infection. While the risk of infection and immunogenicity may be 
minimized by tissue processing methods such as allograft freezing, freeze-drying, and 
ethylene oxide or gamma irradiation sterilization, these processes also decrease allograft 




Demineralized Bone Matrix  
 Demineralized bone matrix (DBM) is produced by acid extraction of allografts 
and is clinically available in a range of forms such as injectable paste, granules, gel, 
putty, or strips. DBM preparations are osteoconductive due to the ECM left behind but 
may exhibit non-uniform osteoinductivity due to donor-to-donor variations as well as 
differences in storage, sterilization and processing methods used
16
.  Although DBM has 
demonstrated osteoinductive properties in
 
animal studies, there have been no randomized, 
controlled human studies involving the
 
use of DBM alone 
22
. It should be noted that 
DBM products with no added components are regulated as minimally modified human 
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tissue and therefore received clearance from the FDA without requiring evidence of 
comparable efficacy to autografts. Products which combine DBM with additives intended 
to improve ease of handling of the DBM product (e.g. DBM-based putty or pastes) are 
now regulated by the FDA as medical devices which require 510(k) clearance. DBM is 
widely used clinically as a ‘bone graft extender’ meaning that it is used in conjunction 
with an autograft, rather than as a replacement for autografts. 
Ceramics 
 Ceramics used as bone grafts include calcium phosphates (BioOss, Osteograf, 
Vitoss, ProOsteon, SRS, Biobon), calcium sulfates and bioglass (Biogran, PerioGlas). 
These materials generally provide some mechanical support and are osteoconductive, but 
not osteoinductive. Ceramics are therefore commonly used as carriers for other 
osteoinductive or bioactive agents such as collagen (Collagraft, Healos), BMPs or cells in 




Bone Morphogenetic Protein-Based Products  
 Although bone morphogenetic protein (BMP)-based bone grafts have emerged as 
promising alternatives to auto and allografts due to their potent bone induction effects, 
they are limited by high costs and serious safety concerns. Since 2002, bone graft 
substitutes using BMP-2 (Medtronic’s InFUSE) and BMP-7 (Stryker’s OP1) have been 
FDA approved for clinical use in the United States 
24, 92, 93
.  Medtronic’s BMP-2 product, 
InFUSE, was approved by the FDA for use in lumbar spinal fusions in conjunction with a 
titanium tapered spinal fusion cage (LT-CAGE Lumber Tapered Fusion Device) using 
the anterior lumber inter fusion (ALIF) surgical technique, which employs an abdominal 
approach.  InFUSE was also approved in 2004 for use in open tibial fractures and in 2007 
for sinus augmentations. Stryker Biotech’s BMP-7 product, OP-1 is approved for use in 
recalcitrant long bone non-unions and certain posterolateral lumbar spinal fusions under a 
20 
 
Humanitarian Device Exemption. Since Medtronic’s InFUSE became commercially 
available, Medtronic quickly become the market leader for bone graft substitutes, 
particularly for spinal fusions. The Journal of the American Medical Association (JAMA) 
reported that nationwide use of BMP-based bone grafts for spinal fusions rose from 
0.69% of all fusions in 2002 to 24.89% of all spinal fusions in 2006
94
. Medtronic now 
controls 44% of the global bone graft market, which is worth $2.5 billion. Medtronic also 
dominates the BMP bone graft market, accounting for 90% of sales. Medtronic’s BMP 
product, the InFUSE bone graft consists of lyophilized recombinant human BMP-2 
(rhBMP-2) which is reconstituted in sterile water at a 1.5 mg/ml concentration and 
applied to a scaffold manufactured from bovine type I Collagen (referred to as an 
absorbable collagen sponge, or ACS) prior to implantation. Despite the rapid increase in 
use of BMP products such as InFUSE as bone grafts since 2002, these products have 
important limitations. First, BMP therapy is extremely expensive; the cost of a single 
treatment kit for InFUSE may range from $2,500 to $,5000 
95
. Secondly, BMPs need to 
be administered at supraphysiological concentrations to stimulate bone growth in 
humans, raising concerns regarding excess bone growth outside the defect site as well as 
inflammatory and carcinogenic effects 
22-24
. Some of these safety concerns may be 
justified; Medtronic and the InFUSE bone graft have faced greater scrutiny in recent 
years with an editorial in a 2011 issue of the Spine Journal alleging that that spinal fusion 
surgeries using the InFUSE bone graft had severe and potentially life-threatening side 
effects which were not reported in the original Medtronic-sponsored clinical studies, and 
that many of the authors of these studies had more than $1 million in financial 
associations with Medtronic
96
. These side effects included ectopic bone formation in the 
spinal canal, radiculopathy, nerve injuries, retrograde ejaculation in males or other 
urogenital adverse events, and potentially lethal swelling of the neck and throat tissue 
following cervical spinal fusions
96
. While the Spine Journal review only addressed safety 
concerns on InFUSE use in spinal fusions, their findings highlight the general risks of 
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introducing extremely high doses of BMPs into patients using carriers without controlled 
release mechanisms. Therefore, there remains an unmet clinical need for cost-effective, 
safe and efficacious bone graft substitutes. 
ECM-MIMETIC BIOMATERIALS FOR ORTHOPAEDIC APPLICATIONS 
Full Length Natural ECM Polymers  
 Due to the important regulatory role that ECM molecules play on cellular 
responses in vivo, full-length ECM proteins have been studied as potential adhesive 









 as well as 
bone sialoprotein
114
 (Table 3). Methods used to functionalize titanium implants with 
ECM polymers include protein adsorption from solution
100, 110
, injection of protein 
solution into a porous implant
99
, dip-coating and covalent tethering
98
 and plasma 
spraying
111







, demineralized bone particles
112
 or cut 
pieces of small intestinal submucosa
113
. Although naturally derived ECM molecules have 
demonstrated some degree of success in selected studies,
97, 98, 113
 the widespread use of 
natural ECM macromolecules in orthopaedic applications has been hindered by several 
factors. First, full-length ECM polymers have low solubility, are costly to extract and 
purify in large quantities, suffer from batch-to-batch variation and potentially suffer from 
immunogenicity. Furthermore, it is challenging to modify, characterize and control the 
presentation of natural ECM biomaterials. 
ECM-Derived Adhesive Peptides/ Proteins  
 The above-mentioned limitations of full-length ECM molecules have spurred the 
use of ECM-derived peptides or recombinant fragments which incorporate the minimal 
functional sequence of their parent protein 
115
 in order to convey bioactivity to implant 
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materials. In contrast to ECM polymers, these peptides and protein fragments may be 
synthesized in larger quantities, immobilized on non-fouling surfaces at high densities, 
and may be tailored in composition for specific applications. While natural ECM proteins 
such as collagens and fibronectin are large macromolecules consisting of thousands of 
amino acids, only a few short peptide sequences within these polymers serve as integrin 
recognition and binding sequences which trigger downstream processes such as adhesion, 
signaling and spreading.  For example, in collagens I, II and III, cells bind to the 
GFOGER
116, 117









 sequences are responsible for cell binding. As a result, short 
peptide sequences such as these, as well as ECM-derived protein fragment such as 
FNIII7-10, are used to biofunctionalize titanium surfaces and bone tissue engineering 
scaffolds
122
. Common peptide/protein fragment functionalization methods for titanium 
implants include simple adsorption or covalent immobilization onto titanium surfaces. 
Peptides may be presented on a non-fouling background by covalently tethering them to 
protein resistant polymer coatings such as polyethylene glycol
122, 123
. Peptide 
modification strategies for bone regeneration within defects include adsorption to 
polymer scaffolds
124




 GFOGER: The hexapeptide sequence Gly-Phe-Hyp-Gly-Glu-Arg (GFOGER) is 
found on residues 502–507 of the 1(I) chain of type I collagen and serves as the major 
recognition site for 21 integrin binding
117, 126, 127
. Our group engineered a Col I-
mimetic GFOGER containing peptide, GGYGGGPC(GPP)5GFOGER(GPP)5GPC, which 
recapitulates the triple helical tertiary structure of native collagen as an adhesive ligand 
for biomaterials. Surfaces presenting adsorbed or covalently immobilized GFOGER 
peptide support equivalent levels of 21 integrin-mediated adhesion of HT1080 
fibrosarcoma and MC3T3-E1 osteoblast-like cells as native collagen I
128
 and also 
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promote osteoblastic differentiation of MC3T3-E1 and primary bone marrow stromal 
cells in vitro
25, 129
. Furthermore, GFOGER enhances bone repair in vivo within rigorous 
critical-sized rat femur defect models without the delivery of cells or growth factors
130
. 
GFOGER-functionalized titanium implants also enhance implant integration in a rat 
cortical model by improving peri-implant bone formation and implant fixation to bone
25, 
129
. Surprisingly, an in vitro study by Hennessy et al. found that adsorption of a different 
triple-helical GFOGER sequence-containing peptide, GPC(GPP)5GFOGER(GPP)5GPC,  
did not improve human mesenchymal stem cell adhesion on hydroxyapatite disks
131
, 
although cells cultured on GFOGER-treated tissue culture plastic showed levels of 
adhesion and spreading equivalent to full-length collagen I. This result contradicts other 
studies by our group and others which indicate that triple-helical peptides containing the 




 and may 
possibly be due to low GFOGER adsorption to the hydroxyapatite disks or variations in 
the primary sequence of the GFOGER peptides used in these studies. 
 DGEA: The DGEA sequence has been suggested as the 21 recognition 
sequence in type I collagen
132
, although a different study failed to demonstrate 21 
mediated cell responses to DGEA
133
. Soluble DGEA peptide inhibits the osteoblastic 
phenotype of rat bone marrow stromal cells cultured on type I collagen. DGEA coated 
hydroxyapatite disks have promoted cell adhesion and upregulated osteoblast marker 
expression in mesenchymal stem cells in vitro
131
. However, surfaces modified with a 
CCGDGEAG peptide failed to support the adhesion of rat calvarial osteoblasts
134
.  
 P15: P15 is a synthetic 15-amino acid peptide derived from the 
(766)GTPGPQGIAGQRGVV(780) sequence found in the 1(I) chain of type I collagen 
135
. Several studies have demonstrated that P15 enhances cell adhesion, osteoblastic gene 
expression and mineralization on anorganic bone matrix (ABM) in vitro
136, 137
 and 




 cranial defects. In a head-to-head 
comparison of DGEA and P15 coated hydroxyapatite disks implanted into rat tibiae, both 
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peptides improved new bone formation, but P15 failed to enhance bone implant 
contact
131
. P15 peptide-coated ABM has also been used in human periodontal osseous 
defects
139, 140
 resulting in better clinical outcomes than open flap debridement alone, and 
has also been used in a pilot clinical study for long-bone defects
141
. However, P15-coated 
ABM has not been compared with ABM alone in these human dental applications to 
determine the role of P-15 alone on the positive effects observed.  
RGD 
 RGD is an adhesive peptide sequence found in many ECM molecules including 
fibronectin, vitronectin, bone sialoprotein and osteopontin
142
. RGD can bind to multiple 
integrins such v3, v1, 81, v8, v6, v5 and IIb3. However, for certain 
integrins, binding to RGD is modulated by another sequence, such as the PHSRN 
synergy site for 51
119, 143
. Because RGD serves as a promiscuous binding sequence, 
many biomaterials have incorporated RGD as an adhesive ligand.  
 The application of linear RGD peptides onto implant surfaces has generally failed 
to enhance functional osseointegration as determined by bone-implant contact and 
mechanical fixation in several independent studies
122, 123, 144, 145
. In addition, Bellis and 
coworkers demonstrated a negative effect for RGD peptides in bone formation and 
osseointegration responses to hydroxyapatite implants
146
.  In contrast to these studies, 
Søballe and colleagues did report enhancements in osseointegration for implants 
presenting cyclic RGD peptides
147, 148
. However, other studies using cyclic RGD have 
also failed to show improvements in implant fixation in rat tibiae 
100
 and canine 
mandibles
149
.  Direct comparison among these contradictory studies is confounded by 
differences in the presence of a non-fouling polymer coating to prevent non-specific 
adsorption of plasma proteins, the animal model used, as well as implant surface finish 
(i.e., roughness). It is worth noting that two studies in which RGD was presented on 
titanium implants in a controlled fashion from non-fouling background coating 
25 
 
demonstrated no improvements in osseointegration
123, 150
, suggesting that RGD-
functionalization is not effective at enhancing implant integration.  Fewer RGD modified 
materials have been tested as bone grafts within defects, but in those studies, as with 




Fibronectin-mimetic Peptides/Protein Fragments 
 Fibronectin contains both the RGD adhesion site as well as a PHSRN synergy 
site. 51 binds to RGD in the presence of PHSRN in fibronectin with a forty-fold 
increase in affinity compared to RGD alone
119
 . Each of these domains independently 
contributes little to binding, but, in combination, they synergistically bind to 51 to 
provide stable adhesion
143, 152
. In contrast, other integrins are unaffected by the synergy 
site and bind only to the RGD site within fibronectin  with a lower affinity than 51
153
. 
Many fibronectin-derived peptides or fragments designed for biomaterial applications 
therefore recapitulate this interaction between 51 and the RGD and PHSRN sites. 
 FNIII7-10: Our group has engineered a recombinant fragment of fibronectin, 
FNIII7-10, which encompasses the 7-10
th
 repeats of native fibronectin and binds 
specifically to the 51 integrin. FNIII7-10 enhances both osteoblast adhesion strength 
and differentiation in vitro 
150
, as well as implant osseointegration in a rat cortical model 
when compared to titanium implants modified with RGD at an equivalent molar surface 
density 
122
. Furthermore, a simple adsorbed coating this fragment exhibits improved bone 
apposition and mechanical fixation to bone when compared to full-length fibronectin as 
fibronectin domains with antagonistic effects are excluded from the fragment 
154
.  
 FNIII9*-10: Martino et al. investigated the osteogenic potential of human MSCs 
on surfaces and hydrogels functionalized with full-length fibronectin (FN), fibronectin 
fragments (FNIII9-10 and FNIII10) and a more 51-specific mutated fibronectin 
fragment (FNIII9*-10) and demonstrated that FNIII9*-10 and FNIII9-10 supported 
26 
 
higher MSC differentiation than FN. Interestingly, the level of osteoblastic differentiation 
for each fragment was correlated with its degree of binding specificity for the 51 
integrin (FNIII9*-10 > FNIII9-10 > FNIII10), which supports other studies suggesting 
that 51 engagement may enhance osteogenesis 
122, 150, 154
. 
 RGD-PHSRN: Synthetic peptides designed to co-present the RGD site and 
PHSRN synergy sites on the same molecule separated by polyglycine linkers result in 
increased adhesion and metabolic activity of primary rat calvarial osteoblasts 
155
 and 
human osteoblast-like cells 
156
 in vitro when compared to surfaces presenting RGD alone. 
Other ECM-derived Peptides  
 Other ECM-derived peptides which have been found to enhance osteoblast 
adhesion and differentiation in vitro include FHRRIKA which is derived from the heparin 
binding site of bone sialoprotein 
157-161
, KRSR, which is a heparin binding sequence 
found on multiple ECM proteins 
161-166
, the bone sialoprotein derived BSP(278-293) 
167
, 
the human vitronectin peptide HVP (351-359) 
168-171
, an osteopontin derived peptide 
172
, 
and a heparin binding peptide, HBP12 
173




CHAPTER 3: THE ROLE OF BETA 1 INTEGRINS IN BONE 
FORMATION DURING DEVELOPMENT 
ABSTRACT 
 Bone development, homeostatis, adaptation, and healing are regulated by multiple 
microenvironmental cues, including integrin signaling. β1 integrins are the most common 
integrins and represent the main integrin binding partners of collagen I, the major ECM 
component of bone. While a large body of in vitro research clearly demonstrates the 
importance of β1 integrins on mineralization, in vivo bone-specific perturbations of β1 
integrins in have demonstrated only mild bone phenotypes thus far. In our study, we 
conditionally deleted β1 integrins in osteolineage cells at three different stages of 
differentiation: (1) mesodermal cells under a Twist 2/Dermo 1 promoter, (2) pre-
osteoblasts under the Osterix promoter and (3) mature osteoblasts/osteocytes under the 
Osteocalcin promoter. We found that β1 integrin deletion in mesodermal cells severely 
impairs prenatal skeletal mineralization and is embryonically lethal. In contrast, β1 
integrin deletion in pre-osteoblasts resulted in viable but runted mice with decreased 
cranial mineralization, tooth defects and increased perinatal mortality. Finally, mice with 
β1 integrin null osteoblasts and osteocytes displayed very mild bone phenotypes and no 
change in femur biomechanics. Taken together, our data suggest that β1 integrins play an 
important role in early bone formation by regulating osteoprogenitor function but are not 




 Bone development, remodeling and bone healing are complex, dynamic processes 
which are regulated by the interaction of osteoblasts and osteoclasts with a variety of 
growth factors and extracellular matrix (ECM) molecules in their environment. Adhesion 
to ECM is primarily mediated by a family of receptors known as integrins, which also 
regulate crucial cell functions such as survival, migration and differentiation
174
. Integrins 
are a family of 24 different αβ heterodimeric receptors 
26
. β1 integrins are the largest sub-
family of integrins, as β1 integrins associate with 12 different α subunits 
26
. 
 β1 integrins are believed to play an important role in bone formation as β1 
integrins are highly expressed in osteoblasts, osteoprogenitors and bone marrow stromal 









 in these cells severely impairs in vitro osteogenic differentiation and 
mineralization. In addition, β1 integrins may also regulate survival, as disruption of 
fibronectin- α5β1 interaction induces apoptosis in differentiated osteoblasts
49
. Although 
these in vitro data strongly suggests that β1 integrins play a crucial role in bone 
formation, in vivo deletion or functional perturbation of β1 integrins result in only mild 
skeletal phenoypes. For example, transgenic mice expressing a dominant negative mutant 
form of the β1 integrin under an osteocalcin promoter display normal bone development 
and only slightly altered responses to the mechanical loading environment
13, 18, 19
. 
Similarly, ablation of β1 integrin under the osteoblast-specific Col I 2.3kb promoter 
20
 
yielded no change in the skeletal structure of transgenic mice
11, 12
.  It should be noted that 
β1 integrins are essential for embryonic development and therefore, global β1 integrin 
knockout mice cannot be used for studies of in vivo β1 integrin function
21
.  
 We considered the possibility that the apparent contradiction between the in vitro 
and in vivo studies may be due to the timing of integrin deletion. We therefore 
hypothesized that β1 integrins play a crucial role in early bone development processes but 
29 
 
are not required for mineralization by fully differentiated osteoblasts. In order to 
separately address the roles of β1 integrins in early osteogenic differentiation and mature 
osteoblast function, we generated conditional knockout mice with β1 integrin deletion 
targeted to osteolineage cells at three different stages: (1) mesodermal cells by expressing 
cre recombinase under the Twist 2 (also known as Dermo 1) promoter (TW2-Cre) 
68
 
which is expressed at E9.5 in somites and branchial arches, (2) osteoprogenitor cells by 
expressing cre recombinase under the Osterix (Sp7) promoter (OSX-Cre) which is first 
expressed at E14.5  (3) mature osteoblasts and osteocytes by expressing cre recombinase 
under the Osteocalcin promoter (OCN-Cre) which is expressed from E17.5 onwards 
69
 
(Figure 3.1).  
 
Figure 3.1. Cre-mediated deletions of floxed genes are targeted to mesodermal lineage 
cells, osteoprogenitor cells and mature osteoblasts respectively inTW2-Cre, OSX-Cre and 




Mouse crosses and genotyping 




/J, as well as 
TW2-Cre mice, B6.129X1-Twist2
tm1.1(cre)Dor
/J, and OSX-Cre mice, B6.Cg-Tg(Sp7-
tTA,tetO-EGFP/cre)1Amc/J were purchased from Jackson Laboratories, and OCN-Cre 
mice were kindly provided by Thomas Clemens. Itgβ1
fl/fl
 mice were mated with Tw2-







-OCN-Cre. In all 





) or with heterozygous conditional knockout 
genotype. Mice were tail clipped after weaning and genotyped by PCR analysis of 
genomic DNA extracted using the Qiagen DNeasy Kit. All protocols were approved by 
the Institutional Animal Care and Use Committee in adherence to federal guidelines for 
animal care.  
Timed mating and embryo harvest 
 Timed matings were performed by placing breeders together in evening prior to 
the onset of the 12-hour dark cycle. Females were checked the following morning for 
plugs. Plugged females were single housed and euthanized at E11.5, E13.5 or E19.5 to 
harvest embryos. Mouse embryos were harvested by removing the uterine horn, 
separating implantation sites and peeling away the decidua and amniotic sac. Embryos 
were tailed clipped for genotyping and fixed in neutral buffered formalin before transfer 
to 70% ethanol for µCT analysis and further processing for histological analysis. 
μCT analysis on E19.5 embryos 
 E19.5 embryos were imaged using a μCT40
175
 using an X-ray intensity of 145 
μA, energy of 55 kVp, integration time of 200 ms, and resolution of 12 μm. The data was 
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evaluated by applying a Gaussian filter (sigma=1, support =1) using a threshold value of 
300 mg HA/ccm. 
μCT analysis on adult mouse calvaria and teeth 
 Mouse were anesthetized in an induction chamber filled with 4% isoflurane, 
maintained at 1.5% isoflurane and non-invasively imaged using a VivaCT (Scanco 
Medical) to determine calvarial and tooth structure. Scans were performed using an X-ray 
intensity of 145 μA, energy of 55 kVp, integration time of 200 ms, and resolution of 30 
μm. The data was evaluated by applying a Gaussian filter (sigma=1, support =1) using a 
threshold value of 540 mg HA/ccm. 
μCT analysis and biomechanical testing on intact femurs 
 To test the effect of β1 integrin deletion on bone development, femurs were 
harvested from littermates and stored at -80 °C until ready for testing. The frozen femur 
specimens were thawed under running tap water and imaged in PBS using a µCT 40 
(Scanco Medical) to determine femur structure. The mid diaphysis and distal femur were 
imaged with an X-ray intensity of 145 μA, energy of 55 kVp, integration time of 200 ms, 
and resolution of 12 μm. The μCT data for the mid diaphysis was evaluated by applying a 
Gaussian filter (sigma = 0.8, support = 1) and a threshold value of 580mg HA/ccm. An 
auto-contour algorithm
176
 was applied to the μCT scans of the distal femur and the 
epiphysis and metaphysic were separately evaluated using threshold values of 530 and 
615 mg HA/ccm respectively. The μCT data was used to determine the moment of inertia 
of the femur mid-diaphysis, which was combined with biomechanical testing data to 
calculate bone material property values. For biomechanical analysis by 3 point bending 
testing, the femurs were loaded onto bending fixtures with lower span lengths of 6.2 mm. 
The femora were loaded to failure at a rate of 0.5 mm/s at the mid diaphysis using the 
858 Mini Bionix II testing system (MTS).  
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Femur fracture healing model 
 A unilateral femur fracture model was used to study fracture healing in 10-13 




 littermate mice. Mice were anesthetized under 
isoflurane, all hair was removed from the left hindlimb, and the skin was swabbed with 
alcohol and cycloheximide. A medial incision was then made along the femur and the 
underlying muscle was blunt dissected to expose the femur. The patella was dislocated to 
expose the condyles. To stabilize the fracture, a hole was made in the exposed condyles 
using a 25G needle, and a pre-cut 25G needle shaft was inserted into the intramedullary 
canal. A custom-made 3-point bending device was used to create a transverse fracture in 
the femur mid diaphysis. The patella was then repositioned over the condyles, the muscle 
was sutured and the skin incision was closed with wound clips
177
. 
Radiography, μCT analysis and biomechanical testing of fracture calluses 
 At 2 and 5 weeks post-bone fracture, mice were radiographically imaged using 
the MX-20 Radiography System (Faxitron Imaging) using an X-ray beam energy setting 
of 23kV and scan time of 15 seconds. Fractured femurs were harvested post-euthanasia 
from mice at 2 and 5 week time points. After harvest, the intramedullary pins were 
carefully removed from the fractured femurs and the fracture calluses were wrapped in 
PBS-soaked gauze and stored at -20 °C. The fracture calluses were thawed under running 
water and μCT imaged using a μCT (Scanco Medical) with an X-ray intensity of 145 μA, 
energy of 55 kVp, integration time of 200 ms, and resolution of 12 μm.  The 3D 
reconstructions were evaluated by applying a Gaussian filter (sigma = 0.8, support = 1) 
and a threshold value set at half the value used to evaluate intact bone. 
Histology 
 Bone samples were fixed in 10% neutral buffered formalin overnight, decalcified 
in 10% EDTA solution and transferred to 70% ethanol for storage at 4 °C. Fracture callus 
samples were processed for embedding in Immunobed resin and sectioned to 2 μm 
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thickness. Other bone samples were embedded in paraffin and sectioned at 5 µm 
thickness. Sections were deplasticized and stained with Safranin O/Fast Green to 
visualize cartilage or with Picrosirius Red to visualize collagen fibers. 
 
RESULTS 
Embryonic lethality in Itgβ1
cKO (TW2)
 mice 
 Eighty six mice produced from mating itgβ1
fl/+-
TW2-cre mice with itgβ1
fl/fl 
mice 










-Tw2-cre (0%) mice, while the 
expected Mendelian ratios were 25% for each genotype (Figure 3.2A). The chi-squared 
value for this genotype distribution was 31.48 with 3 degrees of freedom, and a p-value 
of < 0.0001 (Figure 3.2A), demonstrating that the itgβ1
cKO (TW2) 
genotype was not viable. 











) were indistinguishable from each other in terms of gross appearance, size 








mice are not viable. (A) Live offspring numbers from intercross 
of itgβ1
fl/+-
TW2-cre mice with itgβ1
fl/fl 
mice and chi-square test demonstrate that the 
observed distribution is significantly different from the Mendelian ratio. (B) Radiographs 





 ) and heterozygous itgβ1
fl/+-
TW2-cre (heterozygous itgβ1cko) littermates. 
 
 
 Severe mineralization defects in E19.5 Itgβ1
cKO (TW2)
 embryos 
 In order to study the effects of β1 deletion in the mesoderm on bone formation, 





mice. At E11.5 and E13.5, itgβ1
cKO (TW2) 
embryos were indistinguishable from 
WT and het itgβ1
cKO (TW2) 
littermates (data not shown). However, at E19.5, itgβ1
cko (TW2)
 
embryos were much smaller (<70% length) than WT littermates (Figure 3.3A), and 
displayed large abdominal growths where the umbilical cord point of attachment would 
be expected (Figure 3.3A, cKO 1 and cKO2) as well as  cranial hemorrhaging (Figure 
3.3A cKO3). μCT analysis of E19.5 embryos revealed considerable skeletal 
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mineralization in WT and het itgβ1
cKO (TW2) 
embryos, but severely reduced mineralization 
in the skulls and vertebrae (Figure 3.3B and C, cKO1 and cKO3), or a complete lack of 
skeletal mineralization (cKO2), in itgβ1
cKO (TW2) 
embryos. However, in two itgβ1
cko (TW2) 
embryos (Figure 3.3B and C, cKO1 and cKO3) mineralization in the long bones and ribs, 
and appeared normal, suggesting that β1 integrins may have a more crucial role in 
mineralization of bones formed by intramembranous ossification than those formed by 
osteochondral ossification. The scapula, however, appeared to be mineralized in itgβ1
cko 
(TW2) 
embryos. It is noteworthy that all the itgβ1
cKO (TW2) 
embryos appeared to have 
umbilical cord or vascular defects. The umbilical cords of WT embryos were clearly 
filled with blood (Figure 3.4A (i)), but itgβ1
cKO (TW2) 
embryos appeared to have blood in 
their amniotic sac (Figure 3.4A (ii), cKO1) or displayed an attached umbilical cord 
devoid of blood (Figure 3.4A (iii), cKO2). It is likely that the embryonic lethality in 
itgβ1
cKO (TW2) 
embryos is related to these observed umbilical cord abnormalities, but 
further analyses are required to fully establish the cause of embryonic lethality. In one of 
the uterine horns harvested at E19.5, 2 out of 5 implantation sites were considerably 
smaller than the implantation sites of the WT and itgβ1
cKO
 embryos, suggesting that 
implanted embryos had already degenerated extensively by E19.5 (Figure 3.4A (iv)). We 
attempted to harvest the degenerated remains of the embryos from these implantation 
sites and the putative degenerated embryo is shown in Figure 3.4A (v). Safranin O/Fast 
Green staining of sections from cKO embryo 1 revealed a lack of hypertrophic 
chondrocytes in some skeletal elements, suggesting that a lack of mineralization in some 
skeletal elements of itgβ1
cKO (TW2) 
embryos may be due to a defect in chondrocyte 





Figure 3.3. β1 integrin deficiency in mesoderm results in severe skeletal mineralization 
defects in E19.5 embryos. Stereoscopic images of E19.5 embryos. Double white arrows 














embryos are also smaller than littermates. (B) and (C) MicroCT images of 




embryo skeleton. Scale 




Figure 3.4. Gross deformities of E19.5 embryos and histological evaluation. (A) 
Stereoscopic images indicates a (i) normal blood-filled umbilical cord attached to a WT 




 embryo 1, (iii) 




 embryo 3 (black dashed 
arrow). (iv) Image of the uterine horn of pregnant dam at E19.5 displaying 5 implantation 





 embryo 1. Two other sites (solid arrows) were extremely small 
and appeared severely degenerated. (v) Image of a presumptive resorbed embryo from 
one of the degenerated implantation sites. (B) Safranin O/Fast Green stained sections of 
Itgβ1
cKO (OSX)   
 embryo 1 reveal a lack of hypertrophic chondrocytes within some skeletal 
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elements. (i) Image constructed by stitching 4x micrographs of section. (ii) Micrographs 
of skeletal elements. Scale bars indicate (A) (i) , (ii), (iii) 0.5 cm, (iv) 1 cm  and (v) 0.1 





 mice are runted and exhibit some perinatal mortality 
 In order to study the effect bone phenotype in the absence of β1 integrins in 






OSX-cre mice were mated to 
itgβ1
fl/fl 




) offspring. This intercrossing 
gave rise to offspring in numbers which were approximately equal to the expected 
Mendelian ratios. Of 88 offspring genotyped, 22 (25%) itgβ1
fl/+ 
(WT), 18 (20.4%) 
itgβ1
fl/fl 








) mice were born, while the expected distribution was 25% for 
each genotype. The chi-squared value for this distribution is 1.909 with 3 degrees of 
freedom, and the two-tailed p value is 0.59. Although newborn pups appeared 
indistinguishable from each other, at the 21 day old weaning age, some animals in each 
litter were noticeably smaller than their littermates. After genotyping, we found that both 
male and female itgβ1
cKO (OSX) 
mice were smaller and weighed approximately 25-35% 
less than their littermates and this weight reduction was maintained at 9 weeks (Figure 
3.5A). The weights of both male and female itgβ1
cKO (OSX) 
were significantly lower than 
all other littermates beginning at 27 days old. Female itgβ1
cKO (OSX) 
mouse weights were 
lower than WT littermates at 24 days but not lower than that of het itgβ1
cKO (OSX)
 mice. 
Radiographic analysis of itgβ1
cKO (OSX) 
mice did not revealed any gross skeletal 
deformities, and confirmed that itgβ1
cKO (OSX) 
were proportionally smaller than their 
littermates (Figure 3.5B). It has been reported that young (<6 week old) OSX-Cre 
transgenic mice have reduced body weights compared to wild-type controls and that this 
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growth delay is resolved at 12 weeks of age
178
. However, the reduced body weight which 









) littermates (Figure 3.5A), demonstrating that the growth defect 
observed is a result of β1 deficiency and not a side effect of the OSX-cre expression 
system. We also observed instances of perinatal mortality in itgβ1
cKO (OSX) 
mice. Two out 
of 21 itgβ1
cKO (OSX) 
mice died between 3 and 5 weeks old (9.5% mortality) compared with 
no deaths of young mice observed among littermates of other genotypes. However, the 
mice which died were extremely small, and weighed an average of 4.1g at 4 weeks old, 









 mice are runted. (A) Weights of itgβ1
cKO (OSX) 
 diverge 
significantly from their littermates between 24-27 days and reduced weight in itgβ1
cKO 
(OSX)  
mice continue into adulthood. Blue circles,  itgβ1
fl/fl 
(WT), black circles, itgβ1
fl/+ 
(WT), green circles, het itgβ1
cKO (OSX)   
, red circles, itgβ1
cKO (OSX)
. (B) Radiographs of 5 
week old male (top) and female (bottom) littermates indicate that mice are proportionally 
smaller than their littermates and do not display any gross skeletal deformities. Inset, 
dorsal view of itgβ1
cKO (OSX)   
and WT female littermates. Scale bar  1 cm. * p<0.05 
compared to WT and het itgβ1
cKO (OSX)  






 mice display severe tooth defects 
 We considered the possibility that the reduced weight observed in itgβ1
cKO (OSX) 
mice could be due to a tooth defect (Figure 3.6A). Visual examination of the incisors of 
itgβ1
cKO (OSX) 
mice indicated gross tooth abnormalities. Both the mandibular and 
maxillary incisors of itgβ1
cKO (OSX)
 mice were significantly shorter at both 3 and 5 weeks. 
At 3 weeks, the maxillary and mandibular incisors were barely visible above the gum line 
of itgβ1
cKO (OSX)
 mice. In addition, itgβ1
cKO (OSX) 
incisors were misaligned. μCT analysis 
confirmed that both the maxillary and mandibular incisors in itgβ1
cKO (OSX)
 mice were 
reduced in length at 3, 5 and 8 weeks (Figure 3.6B). The itgβ1
cKO (OSX)
 maxillary incisors 
displayed increased curvature from the lateral view and the tip of one maxillary incisor 
often overlapped the other at 5 and 8 weeks of age. Itgβ1
cKO (OSX)
  mandibular incisors 
were spaced apart from each other and the tips were curved away from each other at 3, 5 
and 8 weeks. The extremely short incisors observed in itgβ1
cKO (OSX)
 mice at 3 weeks 
were accompanied by significantly reduced mineralization of both the mandible and 
maxilla. In contrast to the observed incisor abnormalities, no gross defects were observed 
in itgβ1
cKO (OSX)
 molars. Incisor defects were not observed at 3, 5 or 8 weeks in het 
itgβ1
cKO (OSX)
 mice. In order to determine if the reduced weight in itgβ1
cKO (OSX) 
mice 
(Figure 3.5) was due to a nutritional deficiency caused by incisor defects and difficulty 
for the mice to chew hard food pellets, we fed some litters of mice soft food. Even within 
litters that were provided with a soft diet, itgβ1
cKO (OSX)  
 mice exhibited decreased weight 
compared to their littermates (data not shown). This indicates that the reduced weight 
caused by Osterix-specific β1 integrin deletion is not entirely due to nutritional 
deficiencies caused by abnormal tooth development in itgβ1







Figure 3.6. β1 integrin deficiency in osteoprogenitor cells results in incisor defects.  (A) 
Ventral view of 3 and 5 week old littermates revealed gross tooth deformities in itgβ1
cKO 
(OSX) 
mice.(B) 3D μCT reconstruction  displaying lateral and frontal views of littermate 
skulls and incisors indicate that itgβ1
cKO (OSX)  
mice have short and misaligned incisors. 







 mouse calvaria are under-mineralized 
 μCT analysis of mouse skulls revealed severely reduced mineralization in 
itgβ1
cKO (OSX) 
calvaria compared to WT littermates (Figure 3.7). This phenotype was 
observed in frontal, parietal, interparietal and occipital bones, and was most prominent at 
3 weeks, but persisted at 5 and 8 weeks. Mineralization levels in het itgβ1
cKO (OSX) 
mice 









mice have impaired calvarial mineralization.  3D μCT 





 littermates at 3, 5 and 8 weeks old indicate 
significantly reduced calvarial mineralization in itgβ1
cKO (OSX)  
mice and an intermediate 
phenotype in het itgβ1
cKO (OSX)






mouse femurs have altered structure but heal fractures normally 
 12-week old itgβ1
cKO (OSX)
 femurs analyzed by μCT had abnormal cortical 
structure from a tranverse view (Figure 3.8A (i)). Mid-diaphyseal cortices of itgβ1
cKO 
(OSX)
 mice appeared more triangular in cross-section than the cortices of their littermates. 
While itgβ1
cKO (OSX) 
epiphyses appeared normal (Figure 3.8A (iii)), metaphyses displayed 
increased trabecular spacing (Figure 3.8A (ii)). WT and itgβ1
cKO (OSX)  
fractured femurs 
both developed calluses at 2 weeks post fracture and the callus volume decreased by 5 
weeks post fracture, demonstrating that β1 integrins are not required in  osteoprogenitors 





Figure 3.8. β1 integrin deletion in osteoprogenitors results in abnormal femur 
development, does not inhibit fracture healing in 3 month old mice. (A) 3D μCT 
reconstructions and (B) μCT histomorphometry measures of the mid diaphyseal cortex. 
(C) Radiographs of fractured femurs at 0, 2 and 5 weeks post-fracture. (D) 
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Biomechanical analysis by 3-point bending testing on the mid-diaphysis of intact femurs. 




mice are viable and do not exhibit gross abnormalities 
 Itgβ1 
cKO (OCN)  
mice were born viable in the expected Mendelian frequencies and 
did not exhibit any gross phenotype in terms of size, weight or skeletal structure (data not 
shown).  
OCN-Cre expression is specific to bone 
 X-gal staining of the femurs and tibiae from mice with the Lacz reporter gene for 
Cre-mediated recombination showed that cre recombination due to expression of the 
OCN-Cre transgene was restricted to bone tissue, specifically in the osteocytes in the 
cortical bone of the femur and tibia, in the periosteum and in the growth plate (Figure 
3.9A). As expected, we observed no X-gal staining in the heart, lung, muscle or liver 






Figure 3.9. Cre-mediated excision of DNA under the OCN-Cre promoter is osteoblast 
and osteocyte- specific. (A) Whole-mount x-gal stained (blue) of Lacz reporter/OCN-Cre 
mouse  shows that  cre expression is specific to bone. (B) Cryosections after whole mount 




Femur structure is altered in the absence of β1 integrins in osteocytes/osteoblasts 
but there are no differences in bone mechanical properties 
 To assess the effect of β1 integrin deletion osteoblasts and osteocytes on bone 





 (WT) and β1
fl/fl
/OCN-Cre  (itgβ1 
cKO (OCN)
) littermates by μCT analysis. itgβ1 
cKO 
(OCN)
 femurs had thicker cortices with higher bone volumes (Figure 3.10 A and B (i), 
p<0.05) and moments of inertia. In addition, itgβ1 
cKO (OCN)
 epiphyses displayed increased 
connectivity density, trabecular thickness (Figure 3.10 A and B (ii), p<0.01) and 
trabecular number. In contrast, there was reduced connectivity density and higher 
trabecular thickness in the metaphyses of animals with bone-specific β1 integrin deletion 
(Figure 3.10 A (iii), p<0.01 and 0.05 respectively). Despite this observed difference in 
bone structure, there were no differences in the biomechanical properties of itgβ1
cKO (OCN) 
as measured by three point bending (Figure 3.10D). Ultimate stress, elastic modulus, 








Figure 3.10. Itgβ1 
cKO (OCN) 
mice have altered femur structure, but unaltered 
biomechanical properties. (A) μCT measures and (B) 3D μCT reconstructions for the (i) 
cortex, (ii) epiphysis, (iii) metaphysis and (iv) entire femur. One-way ANOVA with 





Loss of β1 integrins in osteocytes/osteoblasts did not change fracture healing 
capacity 
 In order to examine the effect of β1 integrin deletion on fracture healing potential, 
we created mid-diaphyseal femur fractures in WT and itgβ1 
cKO (OCN)  
mice and evaluated 
their healing over 5 weeks. At 2 weeks post-fracture, both WT and itgβ1 
cKO (OCN)  
mice 
displayed callus formation (Figure 3.11A and B). Five weeks after fracture, the calluses 
for both genotypes of mice remodeled, and no gross structural differences could be 
observed in radiographs or 3D μCT reconstructions (Figure 3.11A and B). μCT measures 
such as callus bone volume at 2 weeks and 5 weeks, as well as the moment of inertia at 5 
weeks, were not different between groups (Figure 3.11C). In addition, 3-point bending 
biomechanical testing on the fracture calluses at 5 weeks post-surgery also showed no 
differences in ultimate stress, elastic modulus, maximum load or work to failure (Figure 
3.12A), showing that β1 integrin deficiency in osteoblasts and osteocytes did not impair 
fracture healing. One representative sample from each group was taken down for 
histological analysis at 2 and 5 weeks post-fracture. Safranin O staining revealed 
considerable cartilage presence in both WT and itgβ1 
cKO (OCN)  
calluses after 2 weeks 
(Figure 3.12B). By 5 weeks post-fracture, there was no longer any cartilage present in 
both WT and itgβ1 
cKO (OCN)  
calluses. Qualitatively, there appeared to be a greater amount 
of cartilage in the WT callus at 2 weeks. There was no difference in the mineral densities 
of either intact bone or 5 week fracture calluses of WT and itgβ1 
cKO (OCN)  
mice (Figure 
3.12C). In agreement with this observation, bone marrow stromal cells s harvested from 
WT and itgβ1 
cKO (OCN)  
mice exhibited no differences in alkaline phosphatase activity at 
14 days after culture in osteogenic media or in mineralization at 21 days after osteogenic 
induction (Figure 3.12D). These results demonstrate that β1 integrin deficiency in 





Figure 3.11. Femur fracture healing is not impaired in itgβ1 
cKO (OCN)  
mice. (A) 
Radiographic images, (B) 3D μCT reconstructions and (C) μCT measures of fractured 
femurs from  WT, n=8 and itgβ1 
cKO (OCN)
 n=8 littermates at (i) 2 and (ii) 5 weeks post-
surgery indicate no differences in fracture healing as a result of β1 integrin deletion under 
an osteocalcin promoter. Bars indicate standard deviation. One-way ANOVA with 
genotype as fixed effect, parents, sex and age as random effects , * p<0.05, ** p<0.01. 






Figure 3.12. Itgβ1 
cKO (OCN) 
 callus mechanics, histomorphometry, mineral density and 
BMSC mineralization are unchanged. (A) 5-week biomechanical analysis by 3-point 
bending and (B) histological evaluation of fractured femurs at 2 and 5 weeks from WT 
and itg β1 
cKO OCN 
 littermates by (i) safranin-o /fast green and (ii) picrosirius red staining. 
(C) μCT evaluation of mineral density in intact femurs and fracture calluses. (D) In vitro 
ALP expression and mineralization (Alizarin red staining, ALZ) of BMSCs after 14 and 
21 days of osteogenic induction respectively. Bars indicate standard deviation. One-way 
ANOVA with genotype as fixed effect, parents and age as random effects, * p<0.05, ** 




 β1 integrins are highly expressed in osteoblasts, osteoprogenitors, and 
perturbation of β1 integrins in vitro
1-10
 results in reduced differentiation and 
mineralization, and survival
49
. However, in vivo studies have failed to demonstrate a 
crucial role for β1 integrins in bone formation. For example, transgenic mice expressing a 
dominant negative mutant form of the β1 integrin under an osteocalcin promoter
13, 18, 19
 as 
well as mice with conditional  β1 integrin deletion under the osteoblast-specific Col I 
2.3kb promoter 
20
  have displayed only mild skeletal phenotypes
11, 12
.  We hypothesized 
that this contradictory result may be due to the timing of β1 integrin deletion in vivo. In 
order to address this hypothesis, we generated transgenic mice with β1 integrin  loss in 
osteolineage cells at three different stages by mating β1 integrin-floxed mice with the 
following transgenic cre-expressing mice: integrin deletion was achieved in (1) 
mesodermal cells such as somites and mesencymal condensations using Twist2-Cre mice 
(TW2-Cre)
68
, (2) osteoprogenitor cells using Osterix-Cre mice (OSX-Cre), and (3) 
mature osteoblasts and osteocytes with Osteocalcin-Cre mice (OCN-Cre) 
69
.  
 We found that β1integrn loss under the Twist-2 promoter resulted in embryonic 
lethality, while the distributions of WT and het itgβ1
cKO (TW2) 
embryos appeared normal. 
While itgβ1
cKO (TW2)
 embryos  appeared indistinguishable from littermates at E11.5 and E 
13.5, isolated E19.5 itgβ1
cKO (TW2)  
embryos were significantly smaller than WT litter 
mates and appeared to have gross structural and functional defects of the umbilical cord 
as well as cranial hemorrhaging. Skeletal mineralization in itgβ1
cKO (TW2) 
embryos was 
markedly reduced, with no mineralization observed at all in one itgβ1
cKO (TW2)
 embryo 
and failure of calvarial and vertebral mineralization displayed in two other itgβ1
cKO (TW2)
 
embryos. Some implantations sites on harvested uterine horns were extremely small, 
indicating degeneration of implanted embryos, and suggesting that lethality may have 
occurred at an early stage in some proportion of the embryos. In contrast, itgβ1
cKO (OSX)
 
mice were viable and born in the expected Mendelian frequency, but demonstrated 
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reduced growth compared to WT littermate controls. Itgβ1
cKO (OSX) 
mice weighed less 
than their control littermates at 27 days and exhibited reduced weight until adulthood. 
Radiographic analysis indicated that itgβ1
cKO (OSX) 
mice suffered from proportional and 
not short-limbed dwarfism. In addition, itgβ1
cKO (OSX) 
displayed severe tooth defects. Both 
maxillary and mandibular incisors were reduced in length and misoriented in itgβ1
cKO 
(OSX)
 mice, while molars appeared grossly normal. igβ1
cKO (OSX) 
calvaria also 
demonstrated impaired mineralization. In addition, itgβ1
cKO (OSX) 
femurs displayed 
decreased mineral density, bone volume and moment of inertia (Imin). However, itgβ1
cKO 
(OSX) 
femurs retained their fracture healing capacity. In contrast, itgβ1
cKO (OCN) 
mice 
displayed only mild skeletal phenotypes. Itgβ1
cKO (OCN) 
animals were viable and born in 
the expected Mendelian ratios. Surprisingly, itgβ1
cKO (OCN) 
femurs showed increased 
cortical thickness, as well as higher trabecular thickness in the epihphysis and 
metaphysis. However, femur biomechanics, as well as the itgβ1
cKO (OCN) 
fracture healing 
response was unchanged. 
 Previous studies of conditional β1 integrin deletions in mice have shown growth 
plate abnormalities, short-limbed dwarfism and perinatal lethality with chondrocyte-
specific integrin deficiencies
179





. Given that β1 integrin deletion under the osteochondroprogenitor 
marker Prx-1 produced viable mice with short-limbed dwarfism and joint defects due to 
deficiencies in growth plate and articular cartilage
180
, we were surprised that itgβ1
cKO 
(TW2) 
mice did not survive embryonic development, since Twist 2 is also expressed in 
osteochondroprogenitor cells. However, there are some differences in cre expression 
under Prx-1 and Twist 2 which may provide an explanation for this observation. While 
the first cre expression in both Prx-1-cre and Twist 2-cre occurs at E9.5, in Prx-1-cre 
embryos, expression is seen in mouse limb buds, while in Twist 2-cre embryos, cre 
expression is seen in somites and branchial arches, but also in skin
67
. Prx-1-cre 
expression may be more restricted to skeletal regions than Twist 2-cre expression. It is 
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likely that the cause of embryonic lethality in itgβ1
cKO (TW2) 
embryos is not related to 
skeletal development because embryos lacking mineralized skeletons usually survive 
embryonic development and die newborn due to respiratory distress, as is seen with 
Runx2 deficient mice
79
. Studies involving the earliest stage deletion of β1 deletion under 





Neither of these studies reported defects in mineralization. Therefore, the severe 
mineralization defects observed in itgβ1
cKO (TW2) 
embryos are probably not due to β1 
deletion in chondrocytes. The presence of umbilical cord defects and cranial 
hemorrhaging in itgβ1
cKO (TW2) 
embryos may indicate embryonic lethality due to vascular 
defects. To our knowledge, the skeletal mineralization phenotype we have seen in 
itgβ1
cKO (TW2)
 E19.5 embryos is the most severe mineralization defect observed in vivo 
due to β1 integrin loss in osteochondro lineage cells. Although one itgβ1
cKO (TW2)
 E19.5 
embryo displayed no skeletal mineralization at all, two other itgβ1
cKO (TW2)
 embryos 
lacked craniofacial and vertebral mineralization but demonstrated mineralized long 
bones, ribs and scapula. The long bones are part of the appendicular skeleton which is 
derived from lateral plate mesoderm cells. However, the vertebrae are part of the axial 
skeleton and derived from sclerotome cells in the somites. In contrast, craniofacial bones 
are derived from a combination of neural crest and mesoderm-derived cells. The 
differential effect on β1 integrin deletion on various skeletal elements may be related to 
their developmental origin. 
 Itgβ1
cKO (OSX)
 mice were viable and displayed reductions in calvarial 
mineralization as well as incisor defects and growth abnormalities. While itgβ1
cKO (OSX)
 
calvaria were poorly ossified compared to age-matched littermates at all the time points 
studied, calvarial mineralization continued to increase with age in the itgβ1
cKO (OSX)
 mice, 
suggesting delayed mineralization in  itgβ1
cKO (OSX)
 calvaria. Some aspects of the itgβ1
cKO 
(OSX)
 phenotypes reported here have also been observed in mice with global deletions of 
the collagen-binding α11 or α2 integrins, as well as in α11+ α2 integrin double 
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knockouts. α11, α2, and α2 +α11 integrin knockout mice exhibit proportional dwarfism 
attributed  to altered IGF-1/GH signaling due diminished GHRH production in the 
hypothalamus 
181
. α11 KO incisors are also shortened
182
, although the incisor defect in 
α11 KO mice  do not appear to be as severe as in in itgβ1
cKO (OSX)
 mice. It is possible that 
the proportional dwarfism and incisor defects in itgβ1
cKO (OSX)
 mice are partly due to 
α11β1 and α2β1integrin deletion. The knockout of ICAP-1 (also known as integrin β1 
binding protein 1), which binds to
183
 and regulates β1 integrin function
184
, results in 
calvarial mineralization defects as well
185
, which also supports a role of β1 integrins in 
calvarial development.   
 We found that β1 integrin deletion in mature osteoblasts and osteocytes resulted 
in subtle structural alterations to cortical and trabecular bone in femurs. The cortical 
thickness as well as trabecular thickness was increased in both the epiphysis and 
metaphysis of itgβ1
cKO (OCN) 
mice. However, the biomechanical properties of femurs were 
unchanged in itgβ1
cKO (OCN) 
mice compared to WT controls. We also found that fracture 
healing was not impaired in in itgβ1
cKO (OCN) 
femurs, as measured by μCT as well as 
mechanical testing. Our data suggests that β1 integrins are not required for osteoblast 
function. These results are supported by previous studies involving β1 integrin deletion 
under an osteocalcin promoter
11, 12
, or expression of a dominant-negative form of the β1 
integrin under an osteocalcin promoter
13, 18
, which have displayed minor phenotypes . 
While these findings suggest an early important role for β1 integrin  in regulating bone 
development, the mechanism by which this occurs is still unknown. Further studies will 
be required to elucidate the role of β1 integrins in regulating early skeletal progenitor 
cells, as well as and how compensation occurs for β1 integrins in osteoblasts, given that 
the majority of bone ECM proteins are β1 integrin ligands. However, these results must 
be interpreted with several qualifications. Although Twist 2 is expressed in osteolineage 
cells, it is not osteolineage specific, and is also expressed in other tissues such as the 





embryos may be modulated by alterations to non-osteolineage cells. We have reported 
empirical observations on the effects of targeted β1 integrin deletions. However, further 





 MSCs, and to determine β1 integrin signaling 
pathways responsible for our observed phenotype. We also note that although we 
observed only minor differences between the bone phenotypes of itgβ1
cKO (OCN)
 mice and 
their wild-type littermates, our analyses have focused on the femurs of 10-13 week old 
mice. Therefore it is possible that transient femur phenotypes in younger mice, or 
alterations in the development of other bones may occur in itgβ1
cKO (OCN)
 mice. 
 In conclusion, we have demonstrated that β1 integrin deficiency in somites and 
mesenchymal condensations induce severe defects in skeletal mineralization. This finding 
highlights that β1 integrins play a crucial role in early skeletal development, especially in 
the calvaria and vertebrae. We have also shown that β1 integrin deletion in osterix-
expressing osteoprogenitors results in a delay in calvarial ossification. In addition, 
itgβ1
cKO (OSX)
 mice display severely shortened maxillary and mandibular incisors, 
indicating that β1 integrins regulates incisor eruption.  However, β1 integrin loss in 
osteoblasts and osteocytes induces only minor changes to bone phenotype and does not 
impair fracture healing. Thus we provide the first in vivo evidence that β1 integrins are 
essential for calvarial development and that the regulatory role of β1 integrins is either 
increasingly diminished or compensated for as skeletal progenitor cells undergo 
commitment and differentiation. 
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CHAPTER 4: INTEGRIN-SPECIFIC BIOFUNCTIONALIZED PEG-
MAL HYDROGELS ENHANCE BONE REGENERATION IN 
MURINE SEGMENTAL DEFECTS 
INTRODUCTION 
 Over 1 million bone grafting, bone excision and fracture repair surgeries are 
performed annually in the US, at cost of approximately $5 billion 
14-17
. While autografts, 
which are usually harvested from the patient’s iliac crest, are the gold standard of care, 
autografts are limited by the available donor graft volume and often cause pain and 
inflammation at the donor site
22
. Allografts are more readily available than autografts but 
are processed to prevent the infection and immunogenicity. These processes decrease 
allograft osteogenicity and structural properties due to the absence of viable cells and 
limit the ability of allografts to remodel, and result in a high complication rate
22, 89-91
. 
These limitations of traditional bone grafts have spurred the development of bone graft 
substitutes such as BMP-containing products which have been widely adopted since 
2002, when BMP-2 and BMP-7 products were approved by the FDA for use in humans. 
While BMP therapy has been successful in stimulating bone formation, the BMP doses 
used clinically are orders of magnitude higher
186
 than physiological concentrations of 
BMP, resulting in high costs of treatment
95
. Furthermore, delivery of supraphysiological 
BMP doses without sustained release mechanisms may result in growth factor diffusion 
away from the defect site and result in complications such as ectopic bone formation, 
nerve injuries
96
, as well as inflammatory and carcinogenic effects 
22-24
. Therefore, there 
remains an unmet clinical need for bone graft substitutes which are safe, cost-effective 
and efficacious. 
 Tissue engineering strategies, which deliver materials, bioactive molecules and/or 
cells in vivo to provide microenvironmental cues which stimulate tissue repair, show 
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great promise in addressing the need for improved bone graft substitutes. Recent efforts 
have focused on biomimetic strategies focused on engineering synthetic ECM analogues 
which promote specific integrin-ECM interactions to direct desired host cells responses
25, 
187, 188
. Integrins are a family of cell surface receptors which mediate cell-extracellular 
matrix interactions and regulate crucial cell functions such as survival, growth, migration 
and differentiation 
27, 29, 30
. Specifically, the interaction of 21 integrins with collagen I 
is a crucial signal for osteoblastic differentiation and matrix mineralization 
3, 4, 41-44
. The 
hexapeptide sequence Gly-Phe-Hyp-Gly-Glu-Arg (GFOGER) is found on residues 502–
507 of the 1(I) chain of type I collagen and serves as the major recognition site for 21 
integrin binding 
117, 126, 127
. Our group has previously engineered a synthetic collagen I-
mimetic GFOGER containing peptide, GGYGGGPC(GPP)5GFOGER(GPP)5GPC, which 
recapitulates the triple helical tertiary structure of native collagen and binds specifically 
to 21 integrins. The GFOGER ligand has been shown to recapitulate the bioactivity of 
collagen I, and is also effective in supporting bone healing and osseointegration in vivo. 
Surfaces presenting adsorbed or covalently immobilized GFOGER peptide support 
equivalent levels of 21 integrin-mediated cell adhesion as native collagen I 
128
 and also 
promote osteoblastic differentiation of MC3T3-E1 and primary bone marrow stromal 
cells in vitro 
25, 129
. Furthermore, simple adsorption of GFOGER to PCL scaffolds 
enhances bone repair in vivo within rigorous critical-sized rat femur defect models 
without the delivery of cells or growth factors 
130
. GFOGER-functionalized titanium 
implants also enhance implant integration in a rat cortical model by improving peri-
implant bone formation and implant fixation to bone 
25, 129
. 
 In this study, we incorporated the adhesive 21 integrin-specific GFOGER 
ligand combined with low dose rhBMP-2 in a protease-degradable PEG-maleimide 
hydrogel and evaluated the regenerative potential of our biomaterial in a murine radial 
segmental defect model. We chose to deliver the bioactive ligand and growth factors 
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within a PEG-maleimide hydrogel because synthetic hydrogels offer advantages such as 
low inflammatory profiles, tailorable mechanical properties and biofunctionality
189, 190
. 
We hypothesized that presentation of the integrin-specific GFOGER in combination with 
sustained, cell-mediated ‘on-demand’ release of low-dose rhBMP-2 would promote 
osteoblastic differentiation of host cells and promote bone regeneration in vivo. 
METHODS 
Hydrogel synthesis and collagen sponge implant preparation 
 GFOGER peptide, GGYGGGPC(GPP)5GFOGER(GPP)5GPC,  (4 kDa peptide, 
12kDa as the self-assembled triple helical molecule) was custom synthesized via solid 
phase synthesis by Activotec (Figure 4.1A). Four- arm, maleimide-end functionalized 
(>95%) PEG macromer (, PEG-MAL, 20 kDa) was purchased from Laysan Bio (Figure 
4.1B). The RGD adhesive peptide GRGDSPC (RGD) and bi-cysteine crosslinker peptide 
GCRDVPMSMRGGDRCG (VPM)
191, 192
 were synthesized by AAPTEC. Carrier-free 
rhBMP-2 was purchased from R&D Biosystems. PEG-MAL hydrogels were synthesized 
by reacting PEG-MAL with adhesive ligands (RGD or GFOGER) followed by rhBMP-2 
and the VPM crosslinking peptide and incubating at 37C (Figure 4.1C). Thin 2D gel discs 
were fabricated by coverslipping gel solutions with sterile coverslips which were treated 
with Sigmacote to increase their hydrophobicity. 1.5 µL of hydrogel was cast within each 
4 mm long polyimide sleeve for ease of handling during in vivo implantation. 3 mm thick 
collagen sponges were cut with a 1 mm diameter biopsy sponge and placed within the 
polyimide sleeves prior to implantation. Polyimide sleeves were laser machined with 200 
μm diameter holes to allow for cell invasion and nutrient transport into the defect site. 
62 
 
hMSC cell culture and differentiation assays 
 hMSCs were obtained from Lonza. hMSCs were cultured in MSCGM (Lonza) 
and seeded for osteogenic differentiation assays at a density of 10,000 cells/cm
2
on thin 
hydrogel surfaces. hMSCs were then cultured for up to 21 days in osteogenic induction 
media (Lonza). After 3 days of culture in osteogenic media, cells were rinsed in PBS and 
incubated in 2 μM calcein and 4 μM ethidium homodimer for 30 minutes for Live/Dead 
staining, and then imaged on a Zeiss microscope At 14 days post-induction, hMSCs were 
assayed for alkaline phosphatase activity (ALP). Briefly, cells were scraped in PBS, 
transferred to cold 50 mM Tris-HCl and sonicated to lyse the cells. The total protein 
content for each lysate sample was determined using a BCA assay kit (Thermo Scientific) 
according to the manufacturer’s instructions. Samples were diluted to the same total 
protein content before assaying for ALP. Samples and ALP standards were loaded into a 
96-well plate, then incubated with MUP substrate at 37 °C for 1 hour and read at 360 nm 
excitation and 465nm emission. Mineral deposition at 21 days post-induction was 
assayed by Alizarin Red staining. Cells were fixed in 10% formalin, rinsed twice in water 
and incubated in 2% Alizarin Red solution for 20 minutes. After 4 washes in water, the 
stained cells were scraped in 10% acetic acid and heated to 85 °C for 10 minutes. The 
supernatant was collected after centrifugation, neutralized with 10% ammonium 
hydroxide and read in a 96-well plate at 405nm. 
Thiol quantification assay 
 We carried out a thiol quantification assay in order to determine the efficiency of 
GFOGER ligand incorporation to PEG-MAL via Michael addition reaction of the thiol 
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containing cysteine amino acid residues with maleimide groups. The thiol measure-IT 
assay kit was purchased from Invitrogen. PEG-MAL was reacted with GFOGER ligand 
at various molar ratios for 1 hour at 37 °C. A 96-well plate was pre-loaded with the 
working solution and PEG-GFOGER reaction mixtures as well as GFOGER standards 
then added to appropriate wells. After 5 minute incubation at room temperature, the plate 
was read at 494nm excitation and 517nm emission. 
Murine radial segmental defect surgery 
 B6129SF2/J wild-type male mice (8-10 week old) were purchased from Jackson 
Laboratories. Mice were anesthetized under isoflurane and fur was removed from the 
right forelimb using a depilatory cream. The forelimb was then swabbed with 
chlorohexidine and alcohol to sterilize the surgical site and a 1.5 cm incision was made in 
the skin. Muscle tissue overlying the ulna and radius were blunt dissected, and a 2.5 mm 
defect was created in the radius using a custom-machined bone cutter, while leaving the 
ulna intact. Hydrogel or collagen sponge placed within polyimide sleeves were implanted 
into the defect by fitting the sleeve over the radius at the proximal and distal ends of the 
defect, so that the hydrogel or collagen sponge filled the defect space. The incision was 
then closed with vicryl suture and wound clips. Mice were provided with a single dose of 
slow release buprenorphine for pain relief and were monitored post-surgery for signs of 
distress, normal eating habits and movement. 
Radiography, μCT analysis and biomechanical evaluation 
 Every two weeks after surgery, radial defects were imaged radiographically with 
the MX-20 Radiography System (Faxitron Imaging) using an X-ray beam energy setting 
of 23kV and scan time of 15 seconds. At 4 and 8 weeks post-surgery, radial defects were 
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non-invasively analyzed by μCT scanning a 3.2 mm length of defect using a VivaCT 
(Scanco Medical) using the following parameters: intensity of 145 μA, energy of 55 kVp, 
integration time of 200 ms, and resolution of 15 μm. Evaluation of bone formation within 
the radial defect was performed by hand contouring 2D slices to include only the radius 
and exclude ulnar bone. The data was evaluated by applying a Gaussian filter (sigma=1, 
support =1) using a threshold value of 540mg HA/ccm. 3D μCT reconstructions display 
the full 3.2 mm length of radius scanned. However, in order to ensure that only new bone 
formation was measured, quantification of bone volume and mineral density within the 
defect was performed by evaluating only the middle 2.0 mm of defect. defect. For 
biomechanical testing, radii were potted win Wood’s metal within a custom potting 
apparatus. After potting, the ulna was cut and the radii were loaded onto a Bose ELF 
3200 testing system. Torque was applied to the samples at 3 degress per second until 
failure. 
GFOGER and rhBMP-2 labeling and FMT analysis 
 Vivotag 800 and Vivotag 680 XL amine reactive NHS ester near infrared (IR) 
dyes were purchased from Perkin Elmer. GFOGER peptide and rhBMP-2 were labeled 
with Vivotag 680 and Vivotag 800 respectively. GFOGER peptide was reconstituted in 
50 mM sodium carbonate buffer, pH 8.5 and reacted with excess Vivotag 800 dissolved 
in PBS for 2 hours at room temperature. rhBMP-2, which was lyophilized in acid, was 
reconstituted in NaOH to obtain an rhBMP-2 solution at neutral pH. rhBMP-2 was 
reacted with excess Vivotag 800 dissolved in PBS for 1 hour at room temperature. 
Labeled GFOGER and rhBMP were both desalted using Zeba 7kD MWCO columns to 
remove unreacted dyes and salts from the solutions, and then snap frozen and lyophilized 
overnight.  GFOGER ligand or rhBMP-2 retention within the defect site was analyzed 
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using a FMT 4000 instrument (Perkin Elmer). Fur was removed from the right forelimb 
of mice and placed within a mouse imaging cassette, with their forelimbs resting on a 
tissue imaging block. Mouse forelimbs were scanned at a source density of 1 mm with a 
total of 65 total source points per scan on the 680 or 790 laser channels for Vivotag 680 
and Vivotag 800 respectively. Vivotag 680 or Vivotag 800 conjugates were selected as 
the agents in the scan setting scans. The IR dye signal was quantified by placing 
rectangular prism-shaped 3D regions of interest markers (ROIs) around the right forelimb 
and thresholding at 0 nM concentration. The total amount of IR dye per animal was 
reported normalized to the day 0 value. For in vitro release studies, Vivotag 800-labeled 
rhBMP-2 was encapsulated within 5ul hydrogels consisting of 4% wt/vol PEG-maleimide 
functionalized with 2mM GFOGER at a final rh-BMP-2 concentration of 0.04 μg/ul. 5ul 
of 0.04 μg/ul rh-BMP-2 was also pipetted into collagen sponges. The hydrogels and 
collagen sponges were each placed in 200ul PBS or 0.1 mg/ml collagenase I solution. 
rhBMP-2 release into from the hydrogel or sponge into solution was measured by taking 
5μl aliquots of the solution at various timepoints and reading their fluorescence values 
using a Xenogen IVIS Lumino II fluorescence imager. 
Histology 
Animals were euthanized 8 weeks after surgery by excess CO2 inhalation and 
their radii and ulna were harvested. Soft tissue was removed carefully without disturbing 
the defect and the bones fixed in 10% neutral buffered formalin overnight. Samples were 
then briefly rinsed in tap water and decalcified in formic acid for two days. The samples 
were then processed for embedding in Immunobed (GMA) resin and sectioned to 2 μm 
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thickness. GAM sections were deplasticized and stained with Safranin O/Fast Green, 
Picrosirius Red or H&E. 
Statistical analysis 
 Data was analyzed by one-way ANOVA with post-hoc Tukey in JMP, or with 





Functionalizing PEG-MAL with GFOGER 
 The thiol containing GFOGER ligand was covalently tethered to PEG-MAL by 
Michael addition reaction (Figure 4.1D) between the thiol groups in the cysteine amino 
acid residues of GFOGER and the maleimide groups in PEG-MAL. In order to determine 
the efficiency of GFOGER peptide tethering efficiency to PEG-MAL, we reacted 
GFOGER peptide with PEG-MAL at varying ratios of maleimide: triple helical 
GFOGER molecule and measured the concentration of free thiols present in the reaction 
mixture, with known concentrations of GFOGER as a standard. GFOGER incorporation 
increased from 0% at a maleimide: GFOGER ratio of 0 to almost 100% at a maleimide: 
GFOGER ratio of 5.5 (Figure 4.1E). Therefore, at a maleimide: GFOGER molar ratio of 
5.5 or higher, all the GFOGER that reacted with PEG-MAL will be incorporated into the 





Figure 4.1. The synthetic GFOGER ligand tethered to PEG-MAL at controlled densities 
and chemically crosslinked to form a protease-degradable hydrogel network. (A) A 
space-filling model of the GFOGER ligand. (B) Chemical structure of branched 4-armed 
PEG-maleimide macromer. (C) Protease sensitive PEG hydrogels incorporating 
GFOGER and BMP-2 are synthesized by reacting PEG-MAL with GFOGER and BMP-2 
and adding a protease-degradable bi-cysteine peptide to form a crosslinked hydrogel 
network. (D) Maleimide groups form covalent bonds with sulhydryl-containing 
molecules at physiological pH by Michael addition to form a thioester linkage. (E) 






hMSC adhesion, viability and differentiation on GFOGER or RGD hydrogels 
 In order to assess if GFOGER functionalized PEG hydrogels could support cell 
adhesion, viability and differentiation, we seeded hMSCs atop thin flat PEG-MAL 
hydrogels functionalized with GFOGER or RGD at equimolar densities. We observed an 
increase in hMSC adhesion and spreading on both GFOGER and RGD hydrogels with 
ligand densities ranging from 0.5 mM to 2 mM (Figure 4.2A), while cells on PEG-only 
(no RGD or GFOGER) and 2 mM non adhesive RDG gels remained rounded and 
supported extremely low levels of adhesion (Figure 4.2A). This intrinsically low 
background of PEG allowed us to detect differences in bioactivity of GFOGER or RGD 
ligands. Live/dead staining of hMSCs after 3 days of culture on hydrogel surfaces 
demonstrated high cell viability on both 2 mM GFOGER and 2 mM RGD surfaces 
(Figure 4.2B). While 2mM GFOGER and RGD surfaces supported similar levels of 
adhesion and viability, alkaline phosphatase activity of hMSCs on GFOGER surfaces 
was significantly higher than on RGD surfaces, p<0.05 (Figure 4.2C). GFOGER 
hydrogels also enhanced in vitro mineralization compared to RGD gels. hMSCs cultured 
on GFOGER surfaces had Alizarin red staining and extraction values which were 30% 





Figure 4.2. hMSC adhesion, viability and differentiation on GFOGER and RGD hydrogel 
surfaces. (A) Micrographs of calcein-stained hMSCs on GFOGER and RGD gel surfaces 
at varying bulk densities of ligand 1 day after seeding. (B) Live/Dead stained hMSCs on 
2 mM GFOGER and 2 mM RGD hydrogel surfaces 3 days after osteogenic induction. 
(C) ALP activity at 14 days and (D) Alizarin Red stain for mineralization at 21 days post 
induction. Scale bar (A) 50 μm and (B) 20 μm. 
 
Bone formation in response to GFOGER and GFOGER/BMP hydrogels 
 To evaluate the effect of GFOGER and GFOGER/BMP hydrogels on bone 
formation, we implanted these materials into murine radial critical-sized segmental 
defects. 2.5 mm long segmental defects (Figure 4.3) were created in the right radii of age-
matched male mice, while leaving the ulna intact (Figure 4.4A, week 0). In a pilot study, 
we established that there were no differences in bone formation within untreated empty 
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defects and defects which received an empty tube implant. We subsequently used empty 
tube implants as our negative controls. The conditions tested were defects treated with 
polyimide tubes with (1) no hydrogel (empty tubes), (2) 4% (wt/v) PEG hydrogels 
functionalized with 2 mM GFOGER (GFOGER), or (3) 4% (wt/v) PEG hydrogels 
modified with 2 mM GFOGER and incorporating 0.03 μg of rh-BMP-2 (GFOGER/0.03 
μg rhBMP-2). While negligible bone formation occurred at the ends defects treated with 
empty tubes, GFOGER and GFOGER/0.03 μg rhBMP-2 treated defects showed 
significantly greater bone regeneration over time (Figure 4.4B and C).  Four out of 6 
GFOGER-treated defects came close to bridging the defects and 5/7 GFOGER/0.03 μg 
rhBMP-2-treated defects bridged after 8 weeks (Figure 4.4B). Despite the increased rate 
of bridging with GFOGER/0.03 μg rhBMP-2 implants compared to GFOGER implants, 
the bone volume values between these groups was not significantly different at 4 or 8 
weeks. In contrast, bone volumes in GFOGER-treated and GFOGER/0.03 μg rhBMP-2-
treated defects were higher than in empty tube defects at 8 weeks post-surgery, p<0.05 
(Figure 4.4C). However, there were no differences in bone mineral density between any 






Figure 4.3. Murine radial segmental defect model. (A) Hydrogels are pre-cast in a 
polyimide sleeve with 200 μm diameter holes along the tube walls. (B) 2.5 mm defects 
are created in the radius (r) while leaving the ulna (u) intact to stabilize the defect. (C) 
Radial defect with hydrogel-sleeve implant, hydrogel is blue for better visualization. (D) 
Sample 3D μCT reconstruction of radial defect 3 days after surgery. (E) Excised radius 







Figure 4.4. Radiographic and μCT evaluation of bone healing in response defects treated 
with GFOGER hydrogels or GFOGER/0.03μg rhBMP-2. (A) Representative 
radiographic images, (B) 3D μCT reconstructions (left) and mineral density mappings on 
saggital sections of the same defects (right) and (C) quantitative μCT measures of radial 
defects at 4 and 8 weeks post-surgery. Scale bar (A) 2mm, (B) 1mm. * p<0.05. 
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Role of adhesive ligand and protease-degradable crosslinker in bone formation 
 To determine the role of the adhesive ligand and protease degradable crosslinker 
GCRDVPMSMRGGDRCG (VPM)  in our biomaterial system, we next tested three types 
of hydrogels within radial segmental defects: (1) 4% PEG-maleimide hydrogels 
functionalized with 2 mM GFOGER and crosslinked with VPM, the MMP-sensitive 
crosslinker (GFOGER), (2) 4% PEG-maleimide hydrogels crosslinked with VPM (PEG-
only) and (3) PEG-maleimide hydrogels crosslinked with DTT, a small molecule 
crosslinker that is not sensitive to MMP-mediated degradation (non-degradable PEG). 
PEG hydrogels crosslinked with the VPM crosslinker peptide has previously been shown 





. In addition, VPM is also sensitive to plasmin-mediated cleavage
191
.  At 4 
weeks, GFOGER treated defects showed bone repair (Figure 4.5B and C). However, 
defects treated with PEG-only hydrogels displayed minimal bone formation. Bone 
defects treated with non-degradable PEG hydrogels showed signs of bone resorption in 
radiographs. At 8 weeks, the radial defect size appeared larger in defects treated with 
non-degradable PEG hydrogels (Figure 4.5B). The bone volume in GFOGER-treated 
defects was significantly greater than that in both PEG-only and non-degradable PEG 





Figure 4.5. Radiographic and μCT evaluation of bone healing in response defects treated 
with protease-degradable GFOGER-modified or PEG-only hydrogels, and non-
degradable PEG hydrogels. (A) Representative radiographic images, (B) 3D μCT 
reconstructions  (left) and mineral density mappings on sagittal sections of the same 
defects (right), (C) quantitative μCT measures of radial defects at 4 and 8 weeks post-
surgery. (D) Diagram of composition of GFOGER, PEG-only and non-degradable 
hydrogels. Scale bar (A) 2mm, (B) 1mm. * p<0.05.
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Effect of BMP-2 dose in GFOGER hydrogels on bone healing 
 Next, we studied the dose response of BMP-2 within our GFOGER hydrogels in 
radial segmental defects. We tested the effects of 4% GFOGER functionalized PEG 
hydrogels with 0 μg, 0.03 μg, 0.06 μg, and 0.3 μg rhBMP-2, with empty tubes serving as 
a negative control. Increasing the BMP dose improved bone formation within the defects 
(Figure 4.6). As observed previously, there was minimal bone healing in defects treated 
with empty tubes. However, as seen in the 3D μCT reconstructions, consistent more than 
70% bridging was observed by week 8 beginning with the 0.03 μg dose by 8 weeks. 
Bridging occurred by 4 weeks for the 0.06 μg and 0.3 μg doses. Bone formation was 
accelerated with the 0.03 μg rhBMP-2 dose, which resulted in increased bone volume at 4 
weeks compared to empty tubes (Figure 4.6D). 8 weeks after surgery, defects treated with 
all BMP-2 doses as well as GFOGER hydrogels with no BMP-2 had higher bone 
volumes than with empty tubes. In addition, the 0.06 μg BMP-2 dose enhanced bone 
regeneration over GFOGER hydrogels alone, while surprisingly, the 0.3 μg BMP-2 dose 
did not. Transverse views of 3D μCT reconstructions reveal that this was because a 0.06 
μg BMP-2 primarily induced bone formation within the radial defect space, while causing 
minimal alterations to the structure of the ulna. In contrast, the high 0.3 μg BMP-2 dose 
resulted mainly in changes to the ulna, which over time encircled the outside of the radius 






Figure 4.6. Radiographic and μCT evaluation of bone healing in response to rhBMP-2 
dose in GFOGER hydrogels. (A) Representative radiographic images, (B) 3D μCT 
reconstructions (left) and mineral density mappings on sagittal sections of the same 
defects (right), (C) transverse view of 3D reconstructions and (D) μCT measures of bone 
formation at 4 and 8 weeks post-surgery. Scale bar (A) 2 mm, (B) 1 mm, (C) 1 mm. * 
p<0.05 compared to empty defect, # p<0.05 compared to GFOGER hydrogel. 
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Hydrogel degradation and BMP-2 release 
 In order to study the in vivo BMP-2 release from our hydrogels as well as the 
degradation and clearance of the hydrogel from the defect space, we labeled GFOGER 
and BMP-2 with near IR dyes, Vivotag 680 and 800 respectively. We then synthesized 
4% PEG-MAL hydrogels incorporating 2 mM labeled GFOGER and 0.3 μg of labeled 
BMP-2 and implanted them within radial defects. The defects were non-invasively 
imaged by FMT to determine the percentage of initially implanted GFOGER and BMP-2 
which remained in the defect site over a 14 day period (Figure 4.7A and B). We found 
that BMP-2 incorporated within GFOGER hydrogels underwent sustained release, with 
as much as 20% of the dose retained 14 days after surgery. When modeled as a one-phase 
decay, the half-life of BMP-2 within the defect was 3.9 days. GFOGER was released 
from the defect site slower than BMP-2. Since the GFOGER ligand is tethered to PEG-
MAL, the rate of GFOGER signal loss is also an indicator of the rate of hydrogel 
degradation. The half-life of labeled GFOGER within the defect is 6.8 days when 
modeled as one-phase decay. Safranin O/Fast Green stained GMA sections of treated 
defects did not stain positively for safranin O at 8 weeks post-surgery (Figure 4.8A and 
B), suggesting either that bone healing within the radial defect does not occur through 
endochondral ossification, or if it does occur by endochondral ossification, that all 
chondrocytes have undergone apoptosis by 8 weeks post-surgery. Bone tissue within 
defect sites in all treatment cases appeared to be non-woven at 8 weeks, and in the empty 
tube condition, the middle of the defect contained mostly cell infiltrate and little bone 
tissue (Figure 4.8B). GFOGER hydrogel remnants were not observed in any of the 
hydrogel-treated defects, indicating that the implanted hydrogel had completely degraded 





Figure 4.7. Evaluation of hydrogel degradation and BMP release. (A) Representative 
FMT images and (B) FMT quantification of % implanted dose retained in radial defect 
space over time in vivo. GFOGER peptide was labelled with near-infrared dye Vivotag 
680 and rhBMP-2 was labelled with Vivotag 800. (C) In vitro release of BMP-2 from 





Figure 4.8. Histological evaluation of bone healing in response to rhBMP-2 dose in 
GFOGER hydrogels at 8 weeks post surgery. GMA sections stained with safranin O/Fast 





 Effect of biomaterial scaffold/delivery on bone healing in radial defect 
 BMP-2 used clinically in delivered within a collagen foam scaffold. Therefore, in 
order to compare our biomaterial to the clinical standard, we next examined the role of 
the scaffold or delivery vehicle on bone formation in response to 0.03 μg BMP-2, the 
lowest dose that we tested in the dose-response study. 0.03 μg BMP-2 was delivered 
within a 4% PEG-maleimide hydrogel functionalized with 2 mM GFOGER (GFOGER/ 
0.03 μg rhBMP-2) or within a collagen foam scaffold (collagen/0.03 μg rhBMP-2). μCT 
evaluation revealed that GFOGER/BMP-2 hydrogel implants induced bone healing to a 
much greater extent  than collagen sponge/BMP-2 implants. 4 weeks after surgery, the 
bone volume in GFOGER/0.03 μg rhBMP-2-treated defects was significantly greater than 
in collagen/0.03 μg rhBMP-2-treated defects, p<0.05 (Figure 4.9A and B). The 
improvement in bone healing induced by GFOGER/0.03 μg rhBMP-2 treatment over 
collagen/0.03 μg rhBMP-2 treatment was even more pronounced at week 8, when the 
bone volume was three times as much in GFOGER hydrogels, p<0.001 (Figure 4.9A and 
B). There was no difference in mineral density between the two groups, although the 
mineral density for each group increased over time. Our analysis of the in vivo release of 
near IR dye-labelled BMP-2 from GFOGER gels and collagen foams indicate that a 
greater percentage of delivered BMP-2 is retained within the defect site at 1 and 5 days 
post implantation in GFOGER gels (Figure 4.10A). The half-life of BMP-2 within 
GFOGER hydrogels in vivo is higher than in collagen foams, although it did not reach 
significance (Figure 4.10A). In vitro release assays confirm that GFOGER hydrogels 
support sustained release of BMP-2 compared to collagen sponges in either PBS (Figure 




Figure 4.9. μCT evaluation of radial defects treated with GFOGER/ 0.03μg rh-BMP-2 or 
collagen sponge/ 0.03μg rh-BMP-2. (A) 3D μCT reconstruction images and (B) μCT 
measures demonstrate improved bone healing in defects treated with GFOGER/ 0.03μg 






Figure 4.10. In vitro and in vivo evaluation of Vivotag 800-labelled BMP-2 release from 
GFOGER hydrogels or collagen sponges.  (A) FMT quantification of % implanted dose 
retained in radial defect space over time in vivo. In vitro release profiles of Vivotag-
BMP-2 from GFOGER hydrogels and collagen sponges in (B) PBS and (C) in 0.1mg/ml 





 Bone grafts are used for spinal, foot and ankle fusions, revision arthroplasty 
surgeries, as well as large, non-healing bone defects caused by injury, cancer resection or 
disease. Because the gold-standard autograft treatments may cause donor pain
22
 and 
processed allografts exhibit limited remodeling
22, 89-91
, growth factor treatments such as 
Infuse (BMP-2 therapy) are becoming more widely used in the clinic. However, BMP 
treatments present cost-effectiveness limitations
95
 and clinical safety concerns
22-24, 96
, 
primarily because BMPs are delivered at supraphysiological doses. Therefore, there is a 
strong motivation to engineer safe and cost-effective materials which reduce the 
therapeutic dose of growth factors required to achieve robust healing of critical sized 
bone defects.  
 This study evaluated the effect of implanted PEG hydrogels incorporating the 
α2β1 integrin-specific ligand GFOGER as well as low doses of BMP-2 on osteoblastic 
differentiation and bone regeneration within a segmental defect.  In vitro, GFOGER 
hydrogels supported approximately equal levels of hMSC adhesion and survival as 
hydrogels functionalized with equimolar densities of the non-integrin selective adhesive 
ligand, RGD (GRGDSPC). While cell adhesion and survival was unaltered on GFOGER 
hydrogels, GFOGER hydrogels supported increased differentiation and mineralization of 
hMSCs compared to RGD. These results indicate that cell adhesion to GFOGER 
promotes osteoblastic differentiation and mineralization. Our group has previously shown 
that GFOGER coatings improve mechanical fixation of titanium implants to bone 
25, 129
, 
and adsorbed GFOGER coatings on PCL scaffolds enhance bone regeneration in a rat 
femoral defects 
130
, and these previous findings further support the pro-osteogenic 
activity of GFOGER in vitro.  
 In vivo, we found that treatment of murine radial defects with MMP-sensitive 
GFOGER-functionalized PEG hydrogels increased bone formation but failed to induce 
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consistent bridging of defects after 8 weeks. However, when we encapsulated low (0.03 
μg or 0.02 mg/ml) doses of BMP-2 within GFOGER hydrogels, we observed defect 
bridging at 8 weeks post-surgery. Since the clinical standard BMP-2 therapy involves 
BMP-2 delivery at a concentration of 1.5 mg/ml within a collagen sponge, the BMP-2 
concentration required for segmental defect healing within GFOGER hydrogels is almost 
an order of magnitude lower than the clinical standard (assuming proportional scaling 
across species).  
 Bone formation in defects treated with PEG-only or non-degradable hydrogels 
supported minimal healing, suggesting that both the presence of an adhesive ligand as 
well as protease-sensitive degradation of the hydrogel are necessary to for the enhanced 




 Analysis of the dose response of BMP-2 within our biomaterial system showed 
that while the low 0.03 μg BMP-2 was sufficient for bridging at 8 weeks, 0.06 μg of 
BMP-2 accelerated bone healing and increased the volume of bone present within the 
bridged defect at 8 weeks. Surprisingly, the highest dose tested, 0.3 μg of BMP-2, 
resulted in decreased levels of bone formation within the defect site compared to the 
medium 0.06 μg dose. We also observed that in mice treated with the high 0.3 μg BMP-2 
dose, there were gross deformations in the structure of the ulna, which expanded, 
encircled the radius and fused with it. We speculate that the observed low levels of radial 
healing in combination with expansion and deformation of the ulna in response to 
treatment with high BMP-2 dose may be due to excessively high growth factor gradients 
causing differentiation and mineralization of osteoprogenitors before they migrated into 





  and high BMP-2 concentrations may favor the latter.  
It is also possible that delivery of hydrogels incorporating the high BMP-2 dose induced 
osteolysis within the defect site. Osteolysis, end-plate resorption and subsidence are 
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potential complications of BMP-2 therapy in spinal fusions
196, 197
, and have been reported 
to occur in up to 20-70% of cases
96
.  Furthermore, BMP receptors are expressed on 
osteoclasts
198




 stimulate osteoclastic bone 
resorption. Regardless of the mechanism, this unanticipated alteration to the ulnar 
structure and decreased bone healing in mice receiving high BMP-2 doses highlights the 
undesired effects of excessive BMP-2 signaling and further underscores the importance 
of  precisely controlling BMP-2 dose, delivery method and release kinetics in order to 
direct appropriate bone formation. Although the medium medium 0.06 μg BMP-2 dose, 
supported the greatest volume of bone formation within the radial defect, the structure of 
the ulna was slightly altered in mice treated with the 0.06 μg BMP-2 dose. In contrast, 
there was little observable impact of the low BMP-2 dose on the ulna, and the low BMP-
2 dose was sufficient to induce defect bridging. We therefore chose to use this low 0.03 
μg BMP-2 dose in our subsequent comparison of delivery vehicles.  
 GFOGER hydrogels provided sustained release of encapsulated growth factor, as 
BMP-2 was retained within the defect site for over two weeks, with a half-life of 4 days. 
Over 10% of the initial BMP-2 signal was still detected at the defect after 14 days. The 
retention time of GFOGER within the defect was even higher than for BMP-2 as the half-
life of labeled GFOGER was 7 days. As GFOGER is covalently tethered to the 4-armed 
PEG-maleimide monomer, the half-life of GFOGER localization at the defect site  is an 
indicator of the degradation and clearance rate of the gel and suggests that over 90% of 
the implanted hydrogel is degraded in 3 weeks.  
 The clinical standard for BMP-2 delivery uses an absorbable collagen sponge as 
the growth factor carrier. When we compared GFOGER hydrogels loaded with low (0.03 
μg ) doses of BMP-2 to the clinical standard, we found that GFOGER hydrogels induced 
three times as much bone formation within the radial defects compared to collagen 
sponges with the same BMP-2 dose (p<0.001). In vivo and in vitro BMP-2 release 
studies indicate that BMP-2 is released more slowly and exhibits prolonged retention 
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within the defect site with GFOGER hydrogel delivery vehicles when compared to 
collagen scaffolds. The tightly crosslinked PEG hydrogel system physically entraps 
BMP-2, and we therefore expected slower BMP-2 release from GFOGER hydrogels than 
from collagen sponges which have an open porous structure.    
 It is likely that the enhanced healing response to low dose BMP-2 delivery within 
GFOGER hydrogel scaffolds in this study are due to a combination of sustained delivery 
of of BMP-2 from the hydrogels as well as the intrinsic pro-osteogenic bioactivity of the 
GFOGER ligand compared to collagen foams. Although collagen scaffolds are approved 
for clinical applications
200
 and have demonstrated favorable cell adhesion properties
201
, 
collagen scaffold implants without delivered growth factors do not induce improvements 
in bone formation
202
. In contrast to collagen sponges, we have observed in this study that 
GFOGER-functionalized PEG hydrogels without encapsulated growth factors promote 
bone regeneration in our study. Other studies have confirmed osteogenic GFOGER 
bioactivity by demonstrating that GFOGER coatings upregulate in vivo osseointegration 
and skeletal regeneration
25, 129, 130
.  In addition, osteoblastic differentiation on GFOGER 
coated surfaces exceed differentiation on collagen coated surfaces, indicating that the 
GFOGER peptide has a greater osteogenic effect than its parent molecule, likely due to 
specific α2β1 integrin specificity achieved by the removal of extraneous collagen 
domains which do not upregulate osteoblastic signaling
128
.  
 Our biomaterial strategy benefits from several advantages. The GFOGER 
hydrogel is completely synthetic, well-defined and highly tunable extracellular matrix 
analog. The modular PEG-MAL hydrogel system also affords great versatility in 
biomaterial design by allowing precise control of PEG weight percent and ligand density, 
proteolytic degradation rate, incorporated growth factor dose, as well as possible 
combinations of ligands or growth factors, suggesting that the results presented here can 
be further optimized. Furthermore, many components of the hydrogel system such as 
PEG-MAL, GFOGER adhesive peptide and VPM crosslinker peptide are commercially 
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available, easy to fabricate and much less expensive than recombinant growth factors. 
The low BMP-2 dose required to support defect bridging with GFOGER hydrogels 
increases the cost-effectiveness of this material while also potentially limiting adverse 
responses currently observed with BMP therapies. In addition, PEG is well tolerated in 
vivo
203, 204
 and is clinically approved in multiple products, which suggests that GFOGER 
hydrogels would be safe for therapeutic use. MMP-sensitive crosslinks within our 
bioartificial matrices allows for fairly rapid, ‘on demand’ release of BMP-2 driven by 
cell-mediated proteolysis. Finally, our PEG-maleimide-based biofunctionalized matrices 
are highly versatile and tunable, as multiple hydrogel properties such as porosity, 
stiffness, degradation rate, adhesive functionality, ligand density and incorporated growth 
factor type and release profile may be tuned by varying the hydrogel composition. 
 Despite the aforementioned advantages of our bioartificial hydrogel matrices, our 
biomaterial has certain limitations. First, BMP-2 is encapsulated within the PEG hydrogel 
and may therefore have reduced residence time within the defect compared to strategies 
which utilize covalent growth factor immobilization affinity to immobilized groups. 
Second, because we have chosen a cell-free biomaterial therapeutic strategy, bone 
formation within our biomaterial relies on endogenous cell invasion. As a result, the 
biomaterial design requires a balance between facilitating cell invasion, which is favored 
by loose and rapidly degrading polymer networks, with the sustained of BMP-2 release, 
which is favored by tight networks and slow biomaterial. Third, we pre-cast hydrogels 
within an impermeable polyimide sleeve to improve the handling of soft hydrogels for 
implantation. Although the plastic sleeve was laser machined with holes to improve 
nutrient transport and cell invasion, the use of an impermeable plastic sleeve is not ideal 
and may contribute to decreased bone healing. Lastly, because the murine radial 
segmental defect model as well as the non-porous sleeve for biomaterial delivery are not 




 In conclusion, we have developed a synthetic bioartificial PEG-MAL based 
matrix which is functionalized with the α2β1 integrin-specific ligand GFOGER and 
provides sustained release of BMP-2. These GFOGER hydrogels lacking BMP-2 
promote bone regeneration in radial segmental defects, while GFOGER hydrogels 
incorporating low-dose BMP-2 induce bridging and improved bone formation compared 
to clinical standard collagen sponges delivering the same BMP-2 dose. Therefore, 
GFOGER-functionalized PEG-MAL hydrogels incorporating low dose BMP-2 may have 





CHAPTER 8: FUTURE CONSIDERATIONS 
Role of beta 1 integrins in bone formation 
 We have observed that β1 integrin deletion in osteochondro progenitor cells under 
the Twist 2 promoter impairs calvarial and vertebral mineralization, while integrin 
deletion under the Osterix promoter induces growth abnormalities, delayed calvarial 
ossification, incisor defects and under-mineralized femurs. While these empirical 
observations suggest that β1 integrins play a crucial role in early bone development by 
regulating osteoprogenitor cells, further studies are required to establish the mechanism 
of regulation. We are currently investigating the mechanism by which β1 integrins 
regulate calvarial development by analyzing the gene expression profiles of calvarial 
tissue in  itgβ1
cKO (OSX) 
embryos at E18.5, shortly after the onset of cre recombinase 
expression in the calvarium. We are also investigating osteoblast and osteoclast numbers, 
as well as chondrocyte morphology within the calvaria and femurs of in itgβ1
cKO (OSX)  
mice in order to determine the cell types responsible for the reduced mineral density, and  
growth abnormalities.   
 We have also observed that that β1 integrin deletion in osteochondro progenitor 
cells under the Twist 2 results in embryonic lethality which occurs after E13.5. By E18.5, 
surviving in itgβ1
cKO (TW2)
 embryos are abnormally small and exhibit impaired skeletal 
mineralization as well as umbilical cord deformities. However, by E18.5, degenerated 
implantation sites are visible on the uterine horn, indicating that developmental 
impairments due to β1 integrin knockout in Twist 2 expressing cells occurs at an earlier 
stage. Future work may include analyzing embryos at intermediate stages such as E15.5 
to determine the stage at which normal embryonic development can no longer occur in 
the absence of β1 integrins in mesodermal cells. Detailed histological analysis of these 
embryos will be required to determine the cause of embryonic lethality. This study will 
elucidate the role of β1 integrins on prenatal development. 
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 We have also found in this study that β1 integrin knockout in mature osteoblasts 
and osteocytes result in only mild alterations to bone phenotypes. This suggests that 
osteoblasts do not require β1 integrins to function, which is surprising given that most 
collagen receptors are β1 integrins. This observation raises the question of how 
osteoblasts adapt to the loss of β1 integrins and maintain necessary adhesions. It is 
possible that compensations in integrin expression and ECM may occur in osteoblasts in 
response to β1 integrin deletions.  
 The β1 sub-family of integrins includes 12 different integrins. Therefore deletions 
of β1 integrin partner α subunits individually or in combination will elucidate the roles of 
specific integrins on bone development as well as redundancies among these integrins in 
regulating the formation of skeletal elements.  
Integrin-specific PEG hydrogels and bone healing 
 
Biomaterials for Enhanced Bone Healing 
We have shown that engineered GFOGER functionalized PEG matrices promote bone 
healing and induce robust bone regeneration within a murine radial segmental defect. 
Furthermore, these engineered bioartificial matrices bridge segmental defects when 
combined with low-dose BMP-2 and induce improved bone regeneration compared when 
compared to collagen sponges incorporating low-dose BMP-2. While these results 
demonstrate the clinical potential of GFOGER PEG hydrogels, the design flexibility of 
our biomaterial system allows us to tune multiple properties of the hydrogel in order to 
optimize its performance as a bone graft substitute.  Although delivery of BMP-2 alone 
has been clinically successful in inducing bone formation within large defects, bone 
healing in large defects is often limited by insufficient vascularization
205
. Furthermore, 
combinations of growth factors such as BMP-2 and PDGF have been shown to promote 
healing within calvarial defects 
206
. Therefore, delivery of angiogenic growth factors or 
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combinations of growth factors within GFOGER hydrogels could be used to promote 
bone regeneration. We are currently investigating the effect on VEFG delivery from 
GFOGER PEG hydrogels on bone healing, In this study, we used a relatively low 4% 
weight by volume concentration of PEG-maleimide as well as the VPM crosslinker 
which undergoes rapid MMP-mediated cleavage to fabricate our hydrogels. A design 
variation using higher PEG concentrations and peptide crosslinkers which undergo less 
rapid cleavage than VPM would provide slower release of encapsulated growth factor, 
which may yield further enhancements in bone healing. The growth factor release profile 
may also be tuned by covalently tethering the growth factor to the PEG-maleimide which 
we have previously demonstrated with VEGF delivery from PEG hydrogels. Because 
rhBMP-2 lacks free cysteines, it is not amenable to Michael addition-mediated 
immobilization to the PEG-maleimide monomer. However, a modified sequence of 
BMP-2 containing free cysteines could be employed to immobilize BMP-2 and further 
improve its release kinetcs. The BMP-2 release profile may also be modified by 
covalently immobilizing BMP-2 affinity domains within the hydrogel. While this study 
has focused on the cell-free delivery of growth factors from GFOGER hydrogels, these 
hydrogels may also be suitable carriers for the delivery of encapsulated stem cells. Such a 
strategy may be especially valuable in older patients or patients with defective stem cells. 
 
GFOGER-Modified PEG Hydrogels for Basic Science Studies 
Integrin-specific GFOGER functionalized PEG hydrogels present a useful biomaterial 
system for basic science studies on the role of bioactive ligands on cell behaviors. PEG 
provides a ‘clean slate’ protein resistant background onto which desired bioactive 
molecules may be functionalized at controlled densities. In addition, the stiffness of the 
hydrogels may be independently controlled by varying the PEG concentration. We are 
currently using PEG maleimide hydrogels to study the interaction of environmental cues 
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such as substrate stiffness, adhesive ligand and ligand density on cell morphology, 
osteoblastic differentiation and mineralization.  
 
Transgenic Models to Study Osteoprogenitor Invasion into Defect 
Bone healing within large defects may be limited by multiple factors such as 
vascularization and osteoprogenitor invasion into the defect which are challenging to 
monitor non-invasively in vivo and are also difficult to model in vitro. Therefore, a 
method which enables non-invasive measurement osteoprogenitor invasion would 
facilitate the rational design of biomaterials for the treatment of large non-healing 
defects.We have bred transgenic mice in which osteochondro progenitor cells express 
luciferase (under the Twist 2 promoter), which enables non-invasive imaging and 
quantification of osteochondro progenitors. Using this transgenic model, we may 
investigate the temporal profile of osteoprogenitor recruitment in response to different 
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